By providing valuable information about the human immunodeficiency virus (HIV), basic research is one of the cornerstones of the Division of AIDS (DAIDS) therapeutic clinical research efforts. Research supported by DAIDS has defined treatment guidelines for HIV infection and associated opportunistic infections, prophylactic regimens for secondary infections, and biological markers for predicting the effectiveness of therapeutics and disease progression.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Stammers, D. K. and Ren, J. (2006) Structural studies on HIV reverse transcriptase related to drug discovery. In: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (Skowron, G. and Ogden, R., eds.), Humana Press, Totowa, NJ, pp. 1–32.
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., and Steitz, T. A. (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor, Science, 256, 1783–1790.
Jacobo-Molina, A., Ding, J. P., Nanni, R. G., et al. (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA, Proc. Natl. Acad. Sci. U.S.A., 90, 6320–6324.
Ren, J., Esnouf, R., Garman, E., et al. (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes, Nat. Struct. Biol., 2, 293–302.
Rodgers, D. W., Gamblin, S. J., Harris, B. A., et al. (1995) The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1, Proc. Natl. Acad. Sci. U.S.A., 92, 1222–1226.
Goff, S. P. (1990) Retroviral reverse transcriptase: synthesis, structure, and function, J. Acquir. Immune Defic. Syndr., 3, 817–831.
De Marzo Veronese, F., Copeland, T. D., De Vico, A. L., et al. (1986) Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV, Science, 231, 1289–1291.
Davies II, J. F., Hostomska, Z., Hostomsky, Z., Jordan, S. R., and Matthews, D. A. (1991) Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase, Science, 252, 88–95.
Fan, N., Rank, K. B., Poppe, S. M., Tarpley, W. G., and Sharma, S. K. (1996) Characterization of the p68/p58 heterodimer of human immunodeficiency virus type 2 reverse transcriptase, Biochemistry, 35(6), 1911–1917.
Bird, L. E., Chamberlain, P. P., Stewart-Jones, G., Ren, J., Stuart, D. I., and Stammers, D. K. (2003) Cloning, expression, purification and crystallization of HIV-2 reverse transcriptase, Protein Expr. Purif., 27, 8–12.
Ren, J., Bird, L. E., Chamberlain, P. P., Stewart-Jones, G. B., Stuart, D. I., and Stammers, D. K. (2002) Structure of HIV-2 reverse transcriptase at 2.35 Å resolution and the mechanism of resistance to non-nucleoside inhibitors, Proc. Natl. Acad. Sci. U.S.A., 99, 14410–14415.
Goody, R. S., Muller, B., and Restle, T. (1991) Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleosides in vivo, FEBS Lett., 291, 1–5.
LeLacheur, S. F. and Simon, G. L. (1991) Exacerbation of dideoxycitidine-induced neuropathy with dideoxyinosine, J. Acquir. Immune Defic. Syndr., 4(5), 538–539.
Zemlicka, J., Freisler, J. V., Gasser, R., and Horwitz, J. P. (1973) Nucleosides XVI. The synthesis of 2′, 3′-dideoxy-3′,4′-didehydronucleosides, J. Org. Chem., 38, 990.
Dube, S., Pragnell, I., Kluge, N., Gaedicke, G., Steinheider, G., and Ostertag, W. (1975) Induction of endogenous and of spleen-forming viruses during diethylsulfoxide-induced differentiation of mouse erythroleukemia cells transformed by spleen focus-forming virus, Proc. Natl. Acad. Sci. U.S.A., 72, 1863–1867.
Mitsuya, H., Weinhold, J., Furman, P., et al. (1985) 3′-Azido-3′-deoxythymidine (BW A509U), Proc. Natl. Acad. Sci. U.S.A., 82, 7096–7100.
Carten, M. and Kessler, H. (2006) Zidovidine, lamivudine, and abacavir. In: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (Scowron, G. and Ogden, R, eds.) Humana Press, Totowa, NJ, pp. 33–76.
Birkus, G., Hitchcock, M., and Cihlar, T. (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors, Antimicrob. Agents Chemother., 46, 716–723.
Hayashi, S., Fine, R. L., Chou, T. C., et al. (1990) In vitro inhibition of the infectivity and replication of human immuno- deficiency virus type 1 by combination of antiretroviral 2′, 3′-dideoxynucleosides and virus-binding inhibitors, Antimicrob. Agents Chemother., 34, 82–88.
Dornsife, R. E., St. Clair, M. H., Huang, A. T., et al. (1991) Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition or normal human marrow progenitor cells, Antimicrob. Agents Chemother., 35, 322–328.
Eron, J. J., Jr., Johnson, V. A., Merrill, D. P., et al. (1992) Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′, 3′-dideoxycytidine in vitro, Antimicrob. Agents Chemother., 36, 1559–1562.
Merrill, D. P., Moonis, M., Chou, T.-C., and Hirsch, M. S. (1996) Lamivudine (3TC) or stavudine (d4T) in two- and three-drug combinations against HIV-1 replication in vitro, J. Infect. Dis., 173, 355–364.
Richman, D., Rosenthal, A. S., Skoog, M., et al. (1991) BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine, Antimicrob. Agents Chemother., 35, 305–308.
Johnson, V. A., Merrill, D. P., Chou, T.-C., and Hirsch, M. S. (1992) Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-α against zidovudine-sensitive or -resistant HIV-1 in vitro, J. Infect. Dis., 166, 1143–1146.
Havlir, D., Tierney, C., Friedland, G., et al. (2000) In vivo antagonism with zidovudine plus stavudine combination therapy, J. Infect. Dis., 182, 321–325.
Vogt, M. W., Hartshorn, K. L., Furman, P. A., et al. (1987) Ribavirin antagonizes the effect of azidothymidine on HIV replication, Science, 235, 1376–1379.
Darbyshire, J. H. and Aboulker, J.-P. (1996) Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals, Lancet, 348, 2–5.
Hammer, S. M., Katzenstein, D. A., Hughes, M. D., et al. for the AIDS Clinical Trial Group Study 175 Study Team (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter, N. Engl. J. Med., 335, 1081–1089.
Connor, E. M., Sperling, R. S., Gelbert, R., et al. (1994) Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment, N. Engl. J. Med., 331(18), 1173–1180.
Yarchoan, R., Mitsuya, H., Myers, C., and Broder, S. (1989) Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides, N. Engl. J. Med., 321(11), 726–738.
The AVANTI Study Group (2000) AVANTI 2: a randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naïve patients, AIDS, 14, 367–373.
Hammer, S. M., Squires, K. E., Hughes, M. D., et al. for the AIDS Clinical Trials Group 320 Study Team (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic milliliter or less, N. Engl. J. Med., 337, 725–732.
Skowron, G., Bratberg, J., and Pauwels, R. (2006) Emtricitabine. In: Reverse Transcriptase Inhibitors of HIV/AIDS Therapy (Skowron, G. and Ogden, R., eds.), Humana Press, Totowa, NJ, pp. 133–156.
Gilead Sciences (2004) Emtriva (Emtricitabine) product information, Gilead Sciences, Foster City, CA.
Shewach, D. S., Liotta, D. C., and Schinazi, R. F. (1993) Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase, Biochem. Pharmacol., 45(7), 1540–1543.
Panel on Clinical Practices for Treatment of HIV Infection (2005) Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, October 6. U.S. Department of Health and Human Services, Washington, DC.
Daluge, S. M., Good, S. S., Faletto, M. B., et al. (1997) 159U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity, Antimicrob. Agents Chemother., 41, 1082–1093.
Vince, R., Hua, M., Brownell, J., et al. (1988) Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro, Biochem. Biophys. Res. Commun., 156, 1046–1053.
Faletto, M. B., Miller, W. H., Garvey, E. P., St. Clair, M. H., Daluge, S. M., and Good, S. S. (1997) Unique intracellular activation of the potent anti-human immunodeficiency virus agent 159U89, Antimicrob. Agents Chemother., 41(5), 1099–1107.
Carter, S. G., Kessler, J. A., and Rankin, C. D. (1990) Activities of (−)-carbovir and 3′-azido-3′-deoxythymidine against human immunodeficiency virus in vitro, Antimicrob. Agents Chemother., 34(6), 1297–1300.
Tisdale, M., Alnadaf, T., and Cousens, D. (1997) Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89, Antimicrob. Agents Chemother., 41, 1094–1098.
St. Clair, M. H., Millard, J., Rooney, J., et al. (1996) In vitro antiviral activity of 41W94 (VX-478) in combination with other antiretroviral agent, Antivir. Res., 29(1), 53–56.
Gallant, J. E., Rodriguez, A., Weinberg, W., et al. (2003) Early non-response to tenefovir DF + abacavir and lamivudine in a randomized trial compared to rm efavirenz + abacavir + lamivudine: ESS 30009 an unplanned interim analysis, 43th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14–17 [abstract H-1722a].
Bristol-Myers Squibb Company (2004) Videx and Videx EC delayed-release capsules enteric-coated beadlets product information, Bristol-Myers Squibb Company, Princeton, NJ.
Skowron, G., Chowdhry, S., and Stevens, M. R. (2006) Stavudine, didanosine, and zalcitabine. In: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (Skowron, G. and Ogden R., eds.), Humana Press, Totowa, NJ, pp. 77–132.
Plagemann, P. G., Wohlhueter, R. M., and Woffendin, C. (1988) Nucleoside and nucleobase transport in animal cells, Biochem. Biophys. Acta, 947(3), 405–443.
Cooney, D. A., Dalal, M., Mitsuya, H., et al. (1986) Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity, Biochem. Pharmacol., 35(13), 2065–2068.
Starnes, M. C. and Cheng, Y. C. (1987) Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro, J. Biol. Chem., 262(3), 988–991.
Faraj, A., Fowler, D. A., Bridges, E. G., and Sommadossi, J. P. (1994) Effects of 2′,3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis, Antimicrob. Agents Chemother., 38(5), 924–930.
Keilbaugh, S. A., Hobbs, G. A., and Simpson, M. V. (1993) Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2′,3′-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate, Mol. Pharmacol., 44(4), 702–706.
Medina, D. J., Tsai, C. H., Hsiung, G. D., and Cheng, Y. C. (1994) Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides, Antimicrob. Agents Chemother., 38(8), 1824–1828.
Roche Laboratories (2002) HIVID (Zalcitabine) product information, Roche Laboratories, Nutley, NJ.
Merigan, T. C., Skowron, G., Bozzette, S. A., et al. (1989) Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study, Ann. Intern. Med., 110(3), 189–194.
Bristol-Myers Squibb Company (2002) Zerit®g (Stavudine) product information, Bristol-Myers Squibb Company, Princeton, NJ.
Ho, H. T. and Hitchcock, M. J. (1989) Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus, Antimicrob. Agents Chemother., 33(6), 844–849.
Hoggard, P. G., Kewn, S., Barry, M. G., Khoo, S. H., and Back, D. J. (1997) Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro, Antimicrob. Agents Chemother., 41(6), 1231–1236.
Squires, K. E., Gulick, R., Tebas, P., et al. (2000) A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individuals with HIV infection: selection of thymidine analog regimen therapy (START I), AIDS, 24(11), 1591–1600.
Eron, J. J., Jr., Murphy, R. L., Peterson, D., et al. (2000) A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II), AIDS, 14(11), 1601–1610.
Carr, A., Chuah, J., Hudson, J., et al. (2000) A randomized, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo 1 study, AIDS, 14(9), 1171–1180.
Murphy, R. L., Brun, S., Hicks, C., et al. (2001) ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results, AIDS, 15(1), F1–F9.
Robbins, G. K., De Gruttola, V., Shafer, R. W., et al. (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection, N. Engl. J. Med., 349(24), 2293–2303.
Siegfried, N. L., Van Deventer, P. J. U., Mahomed, F. A., and Rutherford, G. W. (2006) Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults, Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD004535. DOI: 10.1002/14651858.CD004535.pub2.
Gallant, J. E., Staszewski, S., Pozniak, A. L., et al. (2004) Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial, J. Am. Med. Assoc., 292(2), 191–201.
French, M., Amin, J., Roth, N., et al. (2002) Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: the OzCombo 2 study, HIV Clin. Trials, 3(3), 177–185.
Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children (2003) Guidelines for the use of antiretroviral agents in pediatric HIV infection. Bethesda (MD): U.S. Department of Health and Human services, December 14, 2003.
Monpoux, F., Sirvent, N., Cottalorda, J., Mariani, R., and Lefbvre, J. C. (1997) Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience, AIDS, 11(12), 1523–1525.
Kakuda, T. N. (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity, Clin. Ther., 22(6), 685–708.
Mitsuya, H. and Broder, S. (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphodenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides, Proc. Natl. Acad. Sci. U.S.A., 83(6), 1911–1915.
Shulman, N. and Winters, M. (2006) Resistance to nucleoside and nucleotide reverse transcriptase inhibitors. In: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (Skowron, G. and Ogden, R., eds.), Humana Press, Totowa, NJ, pp. 179–207.
Gallant, J. E., Rodriguez, A. E., Weinberg, W. G., et al. (2005) Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects, J. Infect. Dis., 192, 1921–1930.
Huang, H., Chopra, R., Verdine, G. L., and Harrison, S. C. (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance, Science, 282(5394), 1669–1675.
Sarafianos, S. G., Das, K., Clark, A. D., et al. (1999) Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids, Proc. Natl. Acad. Sci. U.S.A., 96(18), 10027–10032.
Gao, H. Q., Boyer, P. L., Sarafianos, S. G., Arnold, E., and Hughes, S. H. (2000) The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase, J. Mol. Biol., 300(2), 403–418.
Lennerstrand, J., Hertogs, K., Stammers, D. K., and Larder, B. A. (2001) Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of immunodeficiency virus type 1 mutants, J. Virol., 75(15), 7202–7205.
Deval, J., Selmi, B., Boretto, J., et al. (2002) The molecular mechanism of multidrug resistance by the q151m human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues, J. Biol. Chem., 277(44), 42097–42104.
Kaushik, N., Talele, T. T., Pandey, P. K., Harris, D., Yadav, P. N., and Pandey, V. N. (2000) Role of glutamine 151 of human immunodeficiency virus type-1 reverse transcriptase in substrate selection as assessed by site-directed mutagenesis, Biochemistry, 39(11), 2912–2920.
Ray, A. S., Basavapathruni, A., and Anderson, K. S. (2002) Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir, J. Biol. Chem., 277(43), 40479–40490.
Martin, J. L., Wilson, J. E., Haynes, R. L., and Furman, P. A. (1993) Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine, Proc. Natl. Acad. Sci. U.S.A., 90(13), 6135–6139.
Lennerstrand, J., Stammers, D. K., and Larder, B. A. (2001) Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine, Antimicrob. Agents Chemother., 45(7), 2144–2146.
Selmi, B., Boretto, J., Sarfati, S. R., Guerreiro, C., and Canard, B. (2001) Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue, J. Biol. Chem., 276(51), 48466–48472.
Sluis-Cremer, N., Arion, D., Kaushik, N., Lim, H., and Parniak, M. A. (2000) Mutational analysis of Lys65 of HIV-1 reverse transcriptase, Biochem. J., 348(Part 1), 77–82.
White, K. L., Margot, N. A., Chen, S., et al. (2004) The HIV-1 K65R RT mutant utilizes a combination of decreased incorporation and decreased excision to evade NRTI, 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8–11 [abstract 55].
Girouard, M., Diallo, K., Marchand, B., Suzanne, M., and Gotte, M. (2003) Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC, J. Biol. Chem., 278(36), 34403–34410.
Richman, D. D., Guatelli, J. C., Grimes, J., Tsiatis, A., and Gingeras, T. (1991) Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction, J. Infect. Dis., 164(6), 1075–1081.
Boucher, C., O’Sullivan, E., Mulder, J., et al. (1992) Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive patients, J. Infect. Dis., 165(1), 105–110.
Masquelier, B., Descamps, D., Carriere, I., et al. (1999) Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study, Antivir. Ther., 4, 69–77.
Naeger, L. K., Margot, N. A., and Miller, R. D. (2001) Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication, Antivir. Ther., 6, 115–126.
Meyer, P. R., Matsuura, S. E., Mian, A. M., So, A. G., and Scott, W. A. (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase, Moll. Cell, 4, 35–43.
Arion, D., Kaushik, N., McCormick, S., et al. (1998) Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase, Biochemistry, 37, 15908–15917.
Larder, B. A., Kemp, S. D., and Harrigan, P. R. (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy, Science, 269, 696–699.
Tisdale, M., Alnadaf, T., and Cousens, D. (1997) Combination of mutations in human immunodeficiency virus type reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89, Antimicrob. Agents Chemother., 41, 1094–1098.
Zhang, D., Caliendo, A. M., Eron, J. J., et al. (1994) Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother., 38(2), 282–287.
Shirasaka, T., Yarchoan, R., O’Brien, M. C., et al. (1993) Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study, Proc. Natl. Acad. Sci. U.S.A., 90(2), 562–566.
Fitzgibbon, J. E., Howell, R. M., Haberzettl, C. A., {Sperber, S. J.,} Kim, H., and Dubin, D. T. (1993) Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine, Antimicrob. Agents Chemother., 36(1), 153–157.
Wainberg, M. A., Gu, Z., Gao, Q., et al. (1993) Clinical correlates and molecular basis of HIV drug resistance, J. Acquir. Immune Defic. Syndr., 6(Suppl. 1), S36–S46.
Shirasaka, T., Kavlick, M. F., Ueno, T., et al. (1995) Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides, Proc. Natl. Acad. Sci. U.S.A., 92(6), 2398–2402.
Craig, C. and Moyle, G. (1997) The development of resistance of HIV-1 to zalcitabine, AIDS, 11(3), 271–279.
Bossi, P., Yvon, A., Mouroux, M., Huraux, J. M., Agut, H., and Calvez, V. (1998) Mutations in the human immunodeficiency virus type 1 reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages, Res. Virol., 149(6), 355–361.
Lin, P. F., Gonzalez, C. J., Griffith, B., et al. (1999) Stavudine resistance: an update on susceptibility following prolonged therapy, Antivir. Ther., 4(1), 21–28.
Coakley, E. P., Gillis, J. M., and Hammer, S. M. (2000) Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine, AIDS, 14(2), F9–F15.
Deminie, C. A., Bechtold, C. M., Riccardi, K., et al. (1998) Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy, AIDS, 12(1), 110–112.
Mayers, D. L., Japour, A. J., Arduino, J. M., Hammer, M. S., et al. (1994) Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group, Antimicrob. Agents Chemother., 38(2), 307–314.
Whitcomb, J. M., Huang, W., Limoli, K., et al. (2002) Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates, AIDS, 16(15), F41–F47.
Jeffrey, J. L., Feng, J. Y., Qi, C. C. R., Anderson, K. S., and Furman, P. A. (2003) Dioxolane guanosine 5′-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase: steady state and pre-steady state kinetic analyses, J. Biol. Chem., 278(21), 18971–18979.
Mewshaw, J. P., Myrick, F. T., Wakefield, D. A., Hooper, B. J., Harris, J. L., McCreedy, B., and Borroto-Esoda, K. (2002) Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails, AIDS, 29, 11–20.
Gu, Z., Wainberg, M. A., Nguyen-Ba, N., L’Heureux, L., de Muys, J.-M., Bowlin, T. L., and Rando, R. F. (1999) Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants, Antimicrob. Agents Chemother., 43, 2376–2382.
Bazmi, H. Z., Hammond, J. L., Cavalcanti, S. C. H., Chu, C. K., Schinazi, R. F., and Mellors, J. W. (2000) In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (−)-β-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine, Antimicrob. Agents Chemother., 44, {1783–1788.}
Mellors, J. W., Bazmi, H., Chu, C. K., and Schinazi, R. F. (1996) K65R mutation in HIV-1 reverse transcriptase causes resistance to (−)-b-D-dioxolane-guanosine and reverses AZT resistance, 5th International Workshop on HIV Drug Resistance, Whistler, Canada, July 3–6 [abstract 7].
Gu, Z., Gao, Q., Fang, H., Salomon, H., Parniak, M. A., Goldberg, E., Cameron, J., and Wainberg, M. A. (1994) Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine, Antimicrob. Agents Chemother., 38, 275–281.
St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D., and Larder, B. A. (1991) Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase, Science, 253, 1557–1559.
Shirasaka, T., Kavlick, M. F., Ueno, T., Gao, W. Y., Kojima, E., Alcaide, M. L., Chokekijchai, S., Roy, B. M., Arnold, E., and Yarchoan, R. (1995) Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides, Proc. Natl. Acad. Sci. U.S.A., 92, 2398–2402.
Bacheler, L. T. (1999) Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase, Drug Resistance Update, 2(1), {56–67}.
Avexa Press Release (2007) Avexa reports positive Phase IIb result: ATC shows superior activity, Avexa Melbourne, Australia.
Eron, J. J., Kessler, H., Thompson, M., et al. (2000) Clinical HIV suppression after short term monotherapy with DAPD, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20 [abstract 690].
Thompson, M., Richmond, G., Kessler, H., et al. (2003) Preliminary results of dosing of amdoxovir in treatment-experienced patients, 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14 [abstract 554].
Holdich, T., Shiveley, L. A., and Sawyer, J. (2007) Effect of lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers, Antimicrob. Agents Chemother., 51(8), 2943–2947.
Bethell, R. C., Lie, Y. S., and Parkin, N. T. (2005) In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs, Antivir. Chem. Chemother., 16, 295–302.
de Muys, J. M., Gourdeau, H., Nguyen-Ba, N., Taylor, D. L., Ahmed, P. S., Mansour, T., Locas, C., Richard, N., Wainberg, M. A., and Rando, R. F. (1999) Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine, Antimicrob. Agents Chemother., 43, 1835–1844.
Dutschman, G. E., Grill, S. P., Gullen, E. A., et al. (2004) Novel 4′-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity, Antimicrob. Agents Chemother., 48(5), 1640–1646.
Bridges, E. G., Dutschman, G. E., Gullen, E. A., and Cheng, Y.-C. (1996) Favorable interaction of βL(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus, Biochem. Pharmacol., 51, 731–736.
Coates, J. A., Cammack, N., Jenkinson, H. J., Mutton, I. M., Pearson, B. A., Storer, R., Cameron, J. M., and Penn, C. R. (1992) The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro, Antimicrob. Agents Chemother., 36, 202–205.
Doong, S. L., Tsai, C. H., Schinazi, R. F., Liotta, D. C., and Cheng, Y.-C. (1991) Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues, Proc. Natl. Acad. Sci. U.S.A., 88, 8495–8499.
Dutschman, G. E., Bridges, E. G., Liu, S.-H., Gullen, E., Guo, X., Kukhanova, M., and Cheng, Y.-C. (1998) Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-βL(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus βD(+) nucleoside analogs in vitro, Antimicrob. Agents Chemother., 42, 1799–1804.
Lin, T. S., Luo, M. Z., Liu, M. C., Pai, S. B., Dutschman, G. E., and Cheng, Y.-C. (1994) Antiviral activity of 2′,3′-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2′,3′-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro, Biochem. Pharmacol., 47, 171–174.
Lin, T. S., Luo, M. Z., Liu, M. C., Pai, S. B., Dutschman, G. E., and Cheng, Y.-C. (1994) Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV), J. Med. Chem., 37, 798–803.
Lin, T. S., Luo, M. Z., Liu, M. C., Zhu, Y. L., Gullen, E., Dutschman, G. E., and Cheng, Y.-C. (1996) Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-beta-L-cytidine (beta-L-d4C) and 2′,3′-dideoxy 2′,3′-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro, J. Med. Chem., 9, 1757–1759.
Gosselin, G., Schinazi, R. F., Sommadossi, J.-P., Mathé, C., Bergogne, M.-C., Aubertin, A.-M., Kirn, A., and Imbach, J.-L. (1994) Anti-human immunodeficiency virus activities of the \upbeta-L-enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro, Antimicrob. Agents Chemother., 38, 1292–1297.
Schinazi, R. F., Chu, C. K., Peck, A., McMillan, A., et al. (1992) Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes, Antimicrob. Agents Chemother., 36, 672–676.
Coates, J. A., Cammack, N., Jenkinson, H. J., Jowett, A. J., et al. (1992) (−)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro, Antimicrob. Agents Chemother., 36, 733–739.
De Clercq, E. (1994) HIV resistance to reverse transcriptase inhibitors, Biochem. Pharmacol., 47, 155–169.
Larder, B. A. (1995) Viral resistance and the selection of antiretroviral combinations, J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 10(Suppl. 1), S28-S33.
Richman, D. D. (1993) Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents, Antimicrob. Agents Chemother., 37, 1207–1213.
Colucci, P., Pottage, J., Robison, H., et al. (2005) The different clinical pharmacology of elvucitabine (beta-L-Fd4C) enables the drug to be given in a safe and effective manner with innovative drug dosing, 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., December 16–19 [abstract LB-27].
Hoesley, C. J. (2006) Nucleotide analogs. In: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (Scowron, G. and Ogden, R., eds.), Humana Press, Totowa, NJ, pp. 157–178.
Naesens, I., Snocek, R., Andrei, G., et al. (1997) HPMC (adefovir), PMEA (adefovir), and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections, Antivir. Chem. Chemother., 8, 1–23.
Balzarini, J. and De Clerq, E. (1991) 5-Phosphoribosyl-1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active phosphate derivatives, J. Biol. Chem., 266, 8686–8689.
Srinivas, R., Robbins, B., Connelly, M., Gong, Y. F., et al. (1993) Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates, Antimicrob. Agents Chemother., 37(10), 2247–2250.
De Clerq, E. (1997) Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections, Intervirology, 40, 295–303.
Hartmann, K., Balzarini, J., Higgins, J, et al. (1994) In vitro activity of acyclic nucleoside phosphonate derivatives against feline immunodeficiency virus in Crandall feline kidney cells and feline peripheral blood lymphocytes, Antivir. Chem. Chemother., 5, 13–18.
Thormar, H., Balzarini, J., Holý, A., et al. (1993) Inhibition of visna virus replication by 2′,3′-dideoxynucleosides and acyclic nucleoside phosphonate analogs, Antimicrob. Agents Chemother., 37, 2540–2544.
Haesens, L., Balzarini, J., Rosenberg, I., Holý, A., et al. (1989) 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-moloney murine sarcoma virus activity in vivo, Eur. J. Clin. Microbiol., 8, 1043–1047.
Barditch-Crovo, P., Deeks, S., Collier, A., et al. (2001) Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults, Antimicrob. Agents Chemother., 45, 2733–2739.
Farthing, C., Khanlou, H., and Yeh, V. (2003) Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine, and tenofovir in the treatment of naïve HIV-infected patients, 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France, July 13–16 [abstract 43].
Squires, K., Pozniak, A., Pierone, G., et al. (2003) Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial, Ann. Intern. Med., 139, 313–320.
Gu, Z., Gao, I., Fang, H., et al. (1994) Identification of a mutation at codon 65 in the JKKK motif of reverse transcriptase that encodes resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxythiacytidine, Antimicrob. Agents Chemother., 38, 275–281.
Gu, Z., Salomon, H., Cherrington, J., et al. (1995) K65R mutation of human immunodeficiency virus type 1 reverse transcriptose encodes cross-resistance to 9-(2-phosphonyl- methoxyethyl)adenine, Antimicrob. Agents Chemother., 39, 1888–1891.
Wainberg, M. A., Miller, M. D., Quan, Y., et al. (1999) In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA, Antivir. Ther., 4, 87–94.
Rhee, S. Y., Taylor, J., Wadhera, G., et al. (2006) Genotypic predictors of human immunodeficiency virus type 1 drug resistance, Proc. Natl. Acad. Sci. U.S.A., 103, 17355–17360.
Whitcomb, J. M., Parkin, N. T., Chappey, C., Hellmann, N. S., and Petropoulos, C. J. (2003) Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates, J. Infect. Dis., 188, 992–1000.
Delaunay, C., Brun-Vezinet, F., Landman, R., et al. (2005) Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021), J. Virol., 79, 9572–9578.
Gallant, J. E., DeJesus, E., Arribas, J. R., et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV, N. Engl. J. Med., 354, 251–260.
Gallant, J. E., Staszewski, S., Pozniak, A. L., et al. (2004) Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial, J. Am. Med. Assoc., 292, 191–201.
McColl, D. J., Margot, N. A., Wulfsohn, M., et al. (2004) Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate, J. Acquir. Immune Defic. Syndr., 37, 1340–1350.
Parikh, U. M., Bacheler, L., Koontz, D., and Mellors, J. W. (2006) The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations, J. Virol., 80, 4971–4977.
Parikh, U. M., Barnas, D. C., Faruki, H., and Mellors, J. W. (2006) Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level, J. Infect. Dis., 194, 651–660.
Parikh, U. M., Koontz, D. L., Chu, C. K., Schinazi, R. F., and Mellors, J. W. (2005) In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase, Antimicrob. Agents Chemother., 49, 1139–1144.
Trotta, M. P., Bonfigli, S., Ceccherini-Silberstein, F., Bellagamba, R., et al. (2006) Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir, J. Med. Virol., 78, 535–541.
White, K. L., Margot, N. A., Ly, J. K., et al. (2005) A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT, AIDS, 19, 1751–1760.
Wirden, M., Marcelin, A. G., Simon, A., et al. (2005) Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients, J. Med. Virol., 76, 297–301.
Margot, N. A., Waters, J. M., and Miller, M. D. (2006) In vitro HIV-1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine, Antimicrob. Agents Chemother., 50, 4087–4095.
Ross, L. L., Dretler, R., Gerondelis, P., Rouse, E. G., Lim, M. L., and Lanier, E. R. (2006) A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine, AIDS, 20, 787–789.
Delaugerre, C., Roudiere, L., Peytavin, G., et al. (2005) Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF, J. Clin. Virol., 32, 241–244.
Van Houtte, M., Staes, M., Geretti, A., Patterry, T., and Bacheler, L. (2006) NRTI resistance associated with the RT mutation K70E in HIV-1, XV International HIV Drug Resistance Workshop, Sitges, Spain, June 13–17.
Ross, L., Gerondelis, P., Liao, Q., et al., (2005) Selection of the HIV-1 reverse transcriptase mutation K70E in antiretroviral-naive subjects treated with tenofovir/abacavir/lamivudine therapy, XIV International HIV Drug Resistance Workshop, Quebec City, Canada, June 7–11 [abstract S102].
Sluis-Cremer, N., Sheen, S. W., Zelina, S., et al. (2007) Molecular mechanism by which K70E in HIV-1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors, Antimicrob. Agents Chemother., 51(10), 48–53.
Margot, N. A., Isaacson, E., McGowan, I., Cheng, A., and Miller, M. D. (2003) Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses, J. Acquir. Immune Defic. Syndr., 33, 15–21.
Masquelier, B., Tamalet, C., Montes, B., et al. (2004) Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients, Antivir. Ther., 9, 315–323.
Miller, M. D., Margot, N., Lu, B., et al. (2004) Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients, J. Infect. Dis., 189, 837–846.
Squires, K., Pozniak, A. L., Pierone, Jr., G., et al. (2003) Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial, Ann. Intern. Med., 139, 313–320.
Barrios, A., de Mendoza, C., Martin-Carbonero, L., et al. (2003) Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients, J. Clin. Microbiol., 41, 4421–4423.
Chappey, C., Wrin, T., Deeks, S., and Petropoulos, C. (2003) Evolution of amino acid 215 in HIV-1 reverse transcriptase in response to intermittent drug selection, XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, June 10–14 [abstract 32].
de Ronde, A., van Dooren, M., van Der Hoek, L., et al. (2001) Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus, J. Virol., 75, 595–602.
Garcia-Lerma, J. G., Nidtha, S., Blumoff, K., Weinstock, H., and Heneine, W. (2001) Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons, Proc. Natl. Acad. Sci. U.S.A., 98, 13907–13912.
Goudsmit, J., de Ronde, A., de Rooij, E., and de Boer, R. (1997) Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215, J. Virol., 71, 4479–4484.
Yerly, S., Rakik, A., De Loes, S. K., et al. (1998) Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants, J. Virol., 72, 3520–3523.
Van Laethem, K., De Munter, P., Schrooten, Y., et al. (2007) No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs, J. Clin. Virol., 39, 43–47.
Violin, M., Cozzi-Lepri, A., Velleca, R., et al. (2004) Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy, AIDS, 18, 227–235.
Cases-Gonzalez, C. E., Franco, S., Martinez, M. A., and Menendez-Arias, L. (2006) Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine, J. Mol. Biol., 365(2), 298–309.
Clevenbergh, P., Kirstetter, M., Liotier, J. Y., et al. (2002) Long-term virological outcome in patients infected with multi-nucleoside analogue-resistant HIV-1, Antivir. Ther., 7, 305–308.
de Jong, J. J., Goudsmit, J., Lukashov, V. V., et al. (1999) Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs, AIDS, 13, 75–80.
Eggink, D., Huigen, M. C., Boucher, C. A., et al. (2007) Insertions in the beta3-beta4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication capacity, Antivir. Res., 75, 93–103.
Gallego, O., de Mendoza, C., Labarga, P., et al. (2003) Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes, HIV Clin. Trials, 4, 372–381.
Kew, Y., Olsen, L. R., Japour, A. J., and Prasad, V. R. (1998) Insertions into the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase reveal a role for fingers subdomain in processive polymerization, J. Biol. Chem., 273, 7529–7537.
Deval, J., Selmi, B., Boretto, J., et al. (2002) The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its {suppression} using alpha-boranophosphate nucleotide analogues, J. Biol. Chem., 277, 42097–42104.
Feng, J. Y., Myrick, F. T., Margot, N. A., et al. (2006) Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine, Nucleosides Nucleotides Nucleic Acids, 25, 89–107.
Garcia-Lerma, J. G., Gerrish, P. J., Wright, A. C., Qari, S. H., and Heneine, W. (2000) Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1, J. Virol., 74, 9339–9346.
Iversen, A. K., Shafer, R. W., Wehrly, K., et al. (1996) Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy, J. Virol., 70, 1086–1090.
Matsumi, S., Kosalaraksa, P., Tsang, H., et al. (2003) Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants, AIDS, 17, 1127–1137.
Asmuth, D. and Pollard, R. (2006) Nevirapine. In: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (Skowron, G. and Ogden R., eds.), Humana Press, Totowa, NJ, pp. 303–344.
Merluzzi, V. J., Hargrave, K. D., Labadia, M., et al. (1993) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor, Science, 250(4986), 1411–1413.
Koup, R. A., Merluzzi, V. J., Hargrave, K. D., et al. (1991) Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587, J. Infect. Dis., 163(5), 966–970.
Gu, Z., Quan, Y., Li, Z., Arts, E. J., and Wainberg, M. A. (1995) Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays, J. Biol. Chem., 270(52), 31046–31051.
Grob, P. M., Wu, J. C., Cohen, K. A., et al. (1992) Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug, AIDS Res. Hum. Retroviruses, 8(2), 145–152.
Shih, C. K., Rose, J. M., Hansen, G. L., Wu, J. C., Bacolla, A., and Griffin, J. A. (1991) Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors, Proc. Natl. Acad. Sci. U.S.A., 88(21), 9878–9882.
Wu, J. C., Warren, T. C., Adams, J., et al. (1991) A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site, Biochemistry, 30(8), 2022–2026.
Spence, R. A., Kati, W. M., Anderson, K. S., and Johnson, K. A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors, Science, 267(5200), 988–993.
Asfour, F. R. and Haubrich, R. (2006) Resistance to non-nucleoside reverse transcriptase inhibitors. In: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (Skowron, G. and Ogden, R., eds.), Humana Press, Totowa, NJ, pp. 401–424.
Richman, D., Shih, C. K., Lowy, I., et al. (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture, Proc. Natl. Acad. Sci. U.S.A., 88(24), 11241–11245.
De Clercq, E. (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTs) in the therapy of HIV-1 infection, Antivir. Res., 38(3), 153–179.
Cheeseman, S. H., Havlir, D., McLaughlin, M. M., et al. (1995) Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus, J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 8(2), 141–151.
Guay, L. A., Musoke, P., Fleming, T., et al. (1999) Intrapartum and neonatal sungle-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in {Kampala,} Uganda: HIVNET 012 randomised trial, Lancet, 354(9181), 795–802.
de Jong, M. D., Vella, S., Carr, A., et al. (1997) High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication, J. Infect. Dis., 175(4), 966–970.
D’Aquila, R. T., Hughes, M. D., Johnson, V. A., et al. (1996) Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators, Ann. Intern. Med., 124(12), 1019–1030.
Baldanti, F., Paolucci, S., Maga, G., et al. (2003) Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine, AIDS, 17(10), 1568–1570.
Gilbert, P. B., Hanna, G. J., De Gruttola, V., et al. (2000) Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens, AIDS Res. Hum. Retroviruses, 16(14), 1325–1336.
Casado, J. L., Hertogs, K., Ruiz, L., et al. (2000) Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen, AIDS, 14(2), F1–F7.
Briones, C., Soriano, V., Dona, C., Barreiro, P., and Gonzalez-Lahoz, J. (2000) Can early failure with nevirapine be rescued with efavirenz? J. Acquir. Immune Defic. Syndr., 24(1), 76–78.
Huang, W., Gamarnik, A., Limoli, K., Petropoulos, C. J., and Whitcomb, J. M. (2003) Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication, J. Virol., 77(2), 1512–1523.
MacArthur, R. D., Kosmyna, J. M., Crane, L. R., and Kovari, L. (1999) The presence or absence of zidovudine in a nevirapine-containing antiretroviral regimen determines which of two nevirapine-limiting mutations occurs on virulogic failure, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26–28 [abstract 1171].
Antoniou, T. and Tseng, A. L. (2002) Interactions between recreational drugs and antiretroviral agents, Ann. Pharmacother., 36(10), 1598–1613.
Casado, J. L., Moreno, A., Hertogs, K., Dronda, F., and Moreno, S. (2002) Extent and importance of cross-resistance to efaverenz after nevirapine failure, AIDS Res. Hum. Retroviruses, 18(11), 771–775.
Harris, M. and Montaner, J. S. (2000) Clinical uses of non-nucleoside reverse transcriptase inhibitors, Rev. Med. Virol., 10(4), 217–229.
Podzamczer, D. and Fumero, E. (2001) The role of nevirapine in the treatment of HIV-1 disease, Expert Opin. Pharmacother., 2(12), 2065–2078.
Montaner, J. S., Reiss, P., Cooper, D., et al. (1998) A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada, and Australia Study, J. Am. Med. Assoc., 279(12), 930–937.
Floridia, M., Bucciardini, R., Ricciardulli, D., et al. (1999) A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naïve patients with advance disease, J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 20(1), 11–19.
Garcia, F., Knobel, H., Sambeat, M. A., et al. (2000) Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study, AIDS, 14(16), 2485–2494.
Raffi, F., Reliquet, V., Ferre, V., et al. (2000) The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naïve HIV-1-infected adults, Antivir. Ther., 5(4), 267–272.
Nunez, M., Soriano, V., Martin-Carbonero, L., et al. (2002) SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naïve individuals, HIV Clin. Trials, 3(3), 186–194.
Allan, P. S., Arumainayagam, J., Harindra, V., et al. (2003) Sustained efficacy of nevirapine in combination with two nucleoside analogues in the treatment of HIV-infected patients: a 48-week retrospective multicenter study, HIV Clin. Trials, 4(4), 248–251.
Giardiola, J. M., Domingo, P., Gurgui, M., and Vazquez, G. (2000) An open-label, randomized comparative study of stavudine (d4T) + didanosine (ddI) + indinavir versus d4T + ddI + nevirapine (NVP) in treatment of HIV-infected naïve patients, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17–20 [abstract 539].
van Leeuwen, R., Katlama, C., Murphy, R. L., et al. (2003) A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients, AIDS, 17(7), 987–999.
Podzamczer, D., Ferrer, E., Consiglio, E., et al. (2002) A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naïve patients (the Combine Study), Antivir. Ther., 7(2), 81–90.
Wit, F. W. (2000) Experience with nevirapine in previously treated HIV-1-infected individuals, Antivir. Ther., 5(4), 257–266.
Easterbrook, P. J., Newson, R., Ives, N., Pereira, S., Moyle, G., and Gazzard, B. G. (2001) Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens, J. Acquir. Immune Defic. Syndr., 27(4), 350–264.
Sabin, C. A., Fisher, M., Churchill, D., et al. (2001) Long-term follow-up of antiretroviral-naïve HIV-positive patients treated with nevirapine, J. Acquir. Immune Defic. Syndr., 26(5), 462–465.
Matthews, G. V., Sabin, C. A., Mandalia, S., et al. (2002) Virological suppression at 6 months is related to choice of initial regi-men in antiretroviral-naïve patients: a cohort study, AIDS, 16(1), 53–61.
Phillips, A. N., Pradier, C., Lazzarin, A., et al. (2001) Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients, AIDS, 15(18), 2385–2395.
Cozzi-Lepri, A., Phillips, A. N., d’Arminio, M. A., et al. (2002) Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naïve Antiretrovirals (I.Co.N.A.) study, J. Infect. Dis., 185(8), 1063–1069.
Raboud, J. M., Rae, S., Vella, S., et al. (1999) Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV, INCAS study team, J. Acquir. Immune Defic. Syndr., 22(3), 260–266.
Raffi, F., Reliquet, V., Podzamczer, D., and Pollard, R. B. (2001) Efficacy of nevirapine-based HAART in HIV-1-infected treatment-naïve persons with high and low baseline viral loads, HIV Clin. Trials, 2(4), 317–322.
Yozviak, J. L., Doerfler, R. E., and Woodward, W. C. (2001) Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice, HIV Clin. Trials, 2(6), 474–476.
Skowron, G., Street, J. C., and Obee, E. M. (2001) CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy, J. Acquir. Immune Defic. Syndr., 28(4), 313–319.
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team, N. Engl. J. Med., 341(25), 1865–1873.
Jordan, W. C., Jefferson, R., Yemofio, F., et al. (2000) Nevirapine + efavirenz + didanosine: a very simple, safe, and effective once-daily regimen, XIIIth International AIDS Conference, Durban, South Africa, July 9–14 [abstract TuPeB3207].
Olivieri, J. (2002) Nevirapine + efavirenz based salvage therapy in heavily pretreated HIV infected patients, Sex. Transm. Infect., 78(1), 72–73.
Veldkamp, A. I., Harris, M., Montaner, J. S., et al. (2001) The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons, J. Infect. Dis., 184(1), 37–42.
van Leth, F., Phanuphak, P., Ruxrungtham, K., et al. (2004) Comparison of the first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study, Lancet, 363(9417), 1253–1263.
Deeks, S. G., Hellmann, N. S., Grant, R. M., et al. (1999) Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome, J. Infect. Dis., 179(6), 1375–1381.
Manfredi, R. and Chiodo, F. (2001) Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease, Int. J. Antimicrob. Agents, 17(6), 511–516.
Jensen-Fangel, S., Thomsen, H. F., Larsen, L., Black, F. T., and Obel, N. (2001) The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study, J. Acquir. Immune Defic. Syndr., 27(2), 124–129.
Perez-Molina, J. A., Perez, N. R., Miralles, P., et al. (2001) Nelfinavir plus nevirapine plus two NRTIs as salvage therapy for HIV-infected patients receiving long-term retroviral treatment, HIV Clin. Trials, 2(1), 1–5.
Benson, C. A., Deeks, S. G., Brun, S. C., et al. (2002) Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients, J. Infect. Dis., 185(5), 599–607.
Harris, M., Durakovic, C., Rae, S., et al. (1998) A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy, J. Infect. Dis., 177(6), 1514–1520.
Casado, J. L., Dronda, F., Hertogs, K., et al. (2001) Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure, AIDS Res. Hum. Retroviruses, 17(2), 93–98.
Gulick, R. M., Smeaton, L. M., D’Aquila, R. T., et al. (2001) Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373, J. Infect. Dis., 183(5), 715–721.
Sullivan, A. K., Nelson, M. R., Shaw, A., et al. (2000) Efficacy of a nelfinavir- and nevirapine-containing salvage regimen, HIV Clin. Trials, 1(1), 7–12.
Parkin, N. T., Deeks, S. G., Wrin, M. T., et al. (2000) Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients, AIDS, 14(18), 2877–2887.
Lorenzi, P., Opravil, M., Hirschel, B., et al. (1999) Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study, AIDS, 13(2), F17–F21.
Carr, A., Samaras, K., Burton, S., et al. (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors, AIDS, 12(7), F51–F58.
Mauss, S., Corzillius, M., Wolf, E., et al. (2002) Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment, HIV Med., 3(1), 49–55.
Amin, J., Moore, A., Carr, A., et al. (2003) Combined analysis of two years follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2, HIV Clin. Trials, 4(4), 252–261.
Shevitz, A., Wanke, C. A., Falutz, J., and Kotler, D. P. (2001) Clinical perspectives on HIV-associated lipodystrophy syndrome: an update, AIDS, 15(15), 1917–1930.
Martinez, E., Conget, I., Lozano, L., Casamitjana, R., and Gatell, J. M. (1999) Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine, AIDS, 13(7), 805–810.
Barreiro, P., Soriano, V., Blanco, F., Casimiro, C., de la Cruz, J. J., and Gonzalez-Lahoz, J. (2000) Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy, AIDS, 14(7), 807–812.
De Lucca, A., Baldini, F., Cingolani, A., et al. (2000) Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study, AIDS, 14(11), 1655–1656.
Carr, A., Hudson, J., Chuah, J., et al. (2001) HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study, AIDS, 15(14), 1811–1822.
Gonzalez de Requena, D., Nunez, M., Jimenez-Nacher, I., and Soriano, V. (2002) Liver toxicity caused by nevirapine, AIDS, 16(2), 290–291.
Ruiz, L., Negredo, E., Domingo, P., et al. (2001) Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study, J. Acquir. Immune Defic. Syndr., 27(3), 229–236.
Masquelier, B., Neau, D., Chene, G., et al. (2001) Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA, J. Acquir. Immune Defic. Syndr., 28(4), 309–312.
Domingo-P., Matias-Guiu, X., Pujol, R. M., et al. (2001) Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy, J. Infect. Dis., 184(9), 1197–1201.
Negredo, E., Cruz, L., Paredes, R., et al. (2002) Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression, Clin. Infect. Dis., 34(4), 504–510.
Dieleman, J. P., Sturkenboom, M. C., Wit, F. W., et al. (2002) Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression, J. Infect. Dis., 185(9), 1261–1268.
Negredo, E., Ribalta, J., Paredes, R., et al. (2002) Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after {replacing} protease inhibitors by nevirapine, AIDS, 16(10), 1383–1389.
Barreiro, P., Camino, N., De Julian, R., Gonzalez-Lahoz, J., and Soriano, V. (2003) Replacement of protease inhibitors by nevirapine or efavirenz in simplification and rescue interventions: which works better? HIV Clin. Trials, 4(4), 244–247.
Bucciardini, R., Wu, A. W., Floridia, M., et al. (2000) Quality of life outcomes of combination zidovudine-didanosine-nevirapine and zidovudine-didanosine for antriretroviral-naïve advanced HIV-infected patients, AIDS, 14(16), 2567–2574.
Conway, B. (2000) Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine, Clin. Infect. Dis., 30(Suppl. 2), S130-S134.
Murphy, R. L. and Smith, W. J. (2002) Switch studies: a review, HIV Med., 3(2), 146–155.
Gathe, J. C., Jr., Ive, P., Wood, R., et al. (2004) SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1-infected patients, AIDS, 18(11), 1529–1537.
Erickson, D. A., Mather, G., Trager, W. F., Levy, R. H., and Keirns, J. J. (1999) Characterization of the in vitro biotransformation of HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochrome P-450, Drug Metab. Dispos., 27(12), 1488–1495.
Sahai, J., Cameron, W., Salgo, M., et al. (1997) Drug interaction study between saquinavir and nevirapine, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22–26 [abstract 496].
Merry, C., Barry, M. G., Mulcahy, F., et al., (1998) The pharmacokinetics of combination therapy with nelfinavir plus nevirapine, AIDS, 12(10), 1163–1167.
Skowron, G., Leoung, G., Kerr, B., et al. (1998) Lack of pharmacokinetic interaction between nelfinavir and nevirapine, AIDS, 12(10), 1243–1244.
Murphy, R. L., Sommadossi, J. P., Lamson, M., Hall, D. B., Hall, D. B., Myers, M., and Dusek, A. (1999) Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunoderficiency virus type 1, J. Infect. Dis., 179(1), 1116–1123.
Lal, R., Hsu, A., Bertz, R., et al. (1999) Evaluation of the pharmacokinetics of the concurrent administration of ABT-378/ritonavir and nevirapine, 7th European Conference on the Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23–27 [abstract 782].
Luzuriaga, K., Bryson, Y., McSherry, G., et al. (1996) Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children, J. Infect. Dis., 174(4), 713–721.
Verweel, G., Sharland, M., Lyall, H., et al. (2003) Nevirapine use in HIV-1-infected children, AIDS, 17(11), 1639–1647.
Pollard, R. B., Robinson, P., and Dransfield, K. (1998) Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection, Clin. Ther., 20(6), 1071–1092.
Stern, J., Lanes, S., Love, J., Robinson, P., Imperiale, M., and Mayers, D. (2003) Hepatic safety of nevirapine: results of the Boehringer Ingelheim Viramune®g Hepatic Safety Project, XIV International AIDS Conference, Barcelona, Spain, July 7–12 [abstract LBOR15].
Warren, K. J., Boxwell, D. E., Kim, N. Y., and Drolet, B. A. (1998) Nevirapine-associated Stevens-Johnson syndrome, Lancet, 351(9102), 567.
Dodi, F., Alessandrini, A., Camera, M., Gaffuri, L., Morandi, N., and Pagano, G. (2002) Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports, AIDS, 16(8), 1197–1198.
Fagot, J. P., Mockenhaupt, M., Bouwes-Bavinck, J. N., Naldi, L., Viboud, C., and Roujeau, J. C. (2001) Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis, AIDS, 15(14), 1843–1848.
Bourezane, Y., Salard, D., Hoen, B., Vandel, S., Drobacheff, C., and Laurent, R. (1998) DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy, Clin. Infect. Dis., 27(5), 1321–1322.
Lanzafame, M., Rovere, P., De Checchi, G., Trevenzoli, M., Turazzini, M., and Parrinello, A. (2001) Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy, Scand. J. Infect. Dis., 33(6), 475–476.
Cattelan, A. M., Erne, E., Salatino, A., et al. (1999) Severe hepatic failure related to nevirapine treatment, Clin. Infect. Dis., 29(2), 455–456.
Jarrousse, B., Cohen, P., Berlureau, P., Bentata, M., Mahr, A., and Guillevin, L. (1999) Nevirapine induced fulminant hepatitis: presentation of case and analysis of risk factors, 7th European Conference on the Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23–27 [abstract 1009].
Mateu, S., Gurgui, M., Sambeat, M. A., et al. (1999) Cholestatic hepatitis by nevirapine: report of five cases, 7th European Conference on the Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23–27 [abstract 1080].
Clarke, S., Harrington, P., Condon, C., Kelleher, D., Smith, O. P., and Mulcahy, F. (2000) Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy, Int. J. STD AIDS, 11(5), 336–337.
Nunez, M., Lana, R., Mendoza, J. L., Martin-Carbonero, L., and Soriano, V. (2001) Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy, J. Acquir. Immune Defic. Syndr., 27(5), 426–431.
Prakash, M., Porredy, V., Tiyyagura, L., and Bonacini, M. (2001) Jaundice and hepatocellular damage associated with nevirapine therapy, Am. J. Gastroenterol., 96(5), 1571–1574.
Johnson, S., Baraboutis, J. G., Sha, B. E., Proia, L. A., and Kessler, H. A. (2000) Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers, J. Am. Med. Assoc., 284(21), 2722–2723.
Benn, P. D., Mercey, D. E., Brink, N., Scott, G., and Williams, I. G. (2001) Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1, Lancet, 367(9257), 687–688.
Martinez, E., Blanco, J. L., Arnaiz, J. A., et al. (2001) Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy, AIDS, 15(10), 1261–1268.
Gonzalez de Requena, D., Nunez, M., Jimenez-Nacher, I., and Soriano, V. (2002) Liver toxicity caused by nevirapine, AIDS, 16(2), 290–291.
Veldkamp, A. I., Meenhorst, P. L., Mulder, J. W., and Beijnen, J. H. (2001) HAART, or just mini-HAART? J. Acquir. Defic. Syndr., 28(5), 495–496.
Lamson, M., Robinson, P., McDonough, M., Hutman, H. W., MacGregor, T., and Nusrat, R. (2000) The effects of underlying renal or hepatic dysfunction on the pharmacokinetics of nevirapine, XIII International AIDS Conference, Durban, South Africa, July 9–14 [abstract TuPeB3301].
Moyle, G. J. and Conway, B. (2006) Efavirenz. In: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (Skowron, G. and Ogden, R, eds.), Humana Press, Totowa, NJ, pp. 345–373.
Rabel, S. R., Maurin, M. B., Rowe, S. M., and Hussain, M. (1996) Determination of the pKa and pH-solubility behavior of an ionizable cyclic carbamate, (S)-(−)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one (MDP 266), Pharm. Dev. Technol., 1, 91–95.
Starr, S. E., Fletcher, C. V., Spector, S. A., et al., and the PACTG 382 Study Team, for the Pediatric AIDS Clinical Trials Group (2002) Efavirenz liquid formulation in human immunodeficiency virus-infected children, Pediatr. Infect. Dis., 21, 659–663.
Young, S. D., Britcher, S. F., Tran, L. O., et al. (1995) L-743,726 (DMP-266): a novel, highly potent non-nucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother., 39, 2602–2605.
Erickson, J. W. and Burt, S. K. (1996) Structural mechanisms of HIV drug resistance, Ann. Rev. Pharmacol. Toxicol., 36, 545–571.
D’Aquila, R. T. (1994) HIV-1 drug resistance: molecular pathogenesis and laboratory monitoring, Clin. Lab. Med., 14, 393–423.
Arnold, E., Ding, J., Hughes, S. H., and Hostomsky, Z. (1995) Structures of DNA and RNA polymerases and their interactions with nucleic acid substrates, Curr. Opin. Struct. Biol., 5, 27–38.
Winslow, D. L., Garber, S., Reid, C., et al. (1996) Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266, AIDS, 10(11), 1205–1209.
Jeffrey, S., Baker, D., Tritch, R., Rizzo, C., Logue, K., and Bacheler, L. (1998) A resistance and cross-resistance profile for Sustiva (efavirenz, DMP 266), 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5 [abstract 702].
Bacheler, L. T., Anton, E. D., Kudish, P., et al. (2000) Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy, Antimicrob. Agents Chemother., 44(9), 2475–2484.
Jeffrey, S., Corbett, J., and Bacheler, L. (1999) In vitro NNRTI resistance of recombinant HIV carrying mutations observed in efavirenz treatment failures, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31–February 4 [abstract 110].
Bacheler, L. T., Anton, E., Jeffrey, S., George, H., Hollis, G., Abremski, K., and the Sustiva Resistance Study Team (1998) RT gene mutations associated with resistance to efavirenz, 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24–27 [abstract 19].
Bacheler, L., George, H., Hollis, G., Abremski, K., and the Sustiva Resistance Study Team (1998) Resistance to efavirenz (Sustiva) in vivo, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5 [abstract 703].
Hsiou, Y., Ding, J., Das, K., et al. (2001) The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance, J. Mol. Biol., 309, 437–445.
Bacheler, L., Jeffrey, S., Hanna, G., et al. (2001) Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy, J. Virol., 75, 4999–5008.
Brenner, B., Turner, D., Oliveira, M., et al. (2003) A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors, AIDS, 17, F1–F5.
Shulman, N. S., Bosch, R. J., Mellors, J. W., Albrecht, M. A., and Katzenstein, D. A. (2004) Genetic correlates of efavirenz hypersusceptibility, AIDS, 18(13), 1781–1785.
Shulman, N., Zolopa, A. R., Passaro, D., et al. (2001) Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy, AIDS, 15, 1125–1132.
AIDSinfo (2007) U.S. Department of Health and Human Services: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents—December 1, 2007 (http://aidsinfo.nih.gov/guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1).
Mayers, D., Jemsek, J., Eyster, E., et al., for the Efavirenz Clinical Development Team and the DMP 266-044 Study Team (1998) A double-blind, placebo-controlled study to assess the safety, tolerability and antiviral activity of efavirenz (EFV, Sustiva, DMP 266) in combination with open-label zidovudine (ZDV) and lamivudine (3TC) in HIV-1 infected patients [DMP 266-004], 12th World AIDS Conference, Geneva, Switzerland, June 28–July 3 [abstract 22340].
Haas, D. W., Seeking, D., Cooper, R., et al., for the Efavirenz Clinical Development Team and the DMP 266-044 Study Team (1998) A Phase II double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safety of efavirenz (RFV, Sustiva, DMP 266) in combination with open-label zidovudine (ZDV) and lamivudine (3TC) at 36 weeks [DMP 266-005], 12th World AIDS Conference, Geneva, Switzerland, June 28–July 3 [abstract 22334].
Moyle, G. J. (2000) Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection, Curr. Opin. Infect. Dis., 13, 19–25.
BHIVA Writing Committee (2001) British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy, HIV Med., 2, 276–313.
Yeni, P. G., Hammer, S. M., Carpenter, C. C., et al. (2002) Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel, J. Am. Med. Assoc., 288, 222–235.
Department of Health and Human Services (DHHS) (2005) Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents (http://aidsinfo.nih.gov/guidelines/).
Moyle, G. J., Wilkins, E., Leen, C., Cheesbrough, A., Reynolds, B., and Gazzard, B. G. (2000) Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use, AIDS, 14, {1453–1454.}
Keiser, P., Nassar, N., White, C., Koen, G., and Moreno, S. (2001) Comparison of efavirenz-containing regimens to nevirapine-containing regimens in antiretroviral-naive HIV infected patients: a cohort study, 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, Greece, October 28–31 [abstract].
Albrecht, M. A., Borsch, R. J., Liou, S. H., and Katzenstein, D. (2002) ACTG 364: efficacy of nelfinavir (NFV) and/or efavirenz (AFV) in combination with new NRTIs in nucleoside experienced subjects: week-144 study, 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, February {24–28} [abstract 425-W].
Moyle, G., Baldwin, C., Mandalia, S., Comitis, S., Burn, P., and Gazzard, B. (2001) Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort, J. Acquir. Immune Defic. Syndr., 28, {399–401.}
Katlama, C., Rachilis, A., Staszewski, S., and the Study 027 and 049 Teams (2001) Better virologic suppression after substitution of protease inhibitors with efavirenz in patients with unquantifiable viral loads, 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, Greece, October 28–31 [abstract].
Hirschel, B., Flepp, M., Bucher, H. C., et al., and the Swiss HIV Cohort (2002) Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort, AIDS, 16, 381–385.
Starr, S. E., Fletcher, C. V., Spector, S. A., et al., for the Pediatric AIDS Clinical Trials Group 382 Team (1999) Combination therapy with efavirenz, nelfinavir, and nucleoside {reverse-transcriptase} inhibitors in children with human immunodeficiency virus type 1, N. Engl. J. Med., 341, 1874–1881.
McComsey, G., Alvarez, A., Joseph, J., Rathore, P., and Lederman, M. (2001) Is simplification of HAART safe in HIV-infected children? First pediatric swith study, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4–8 [abstract 679].
Bacheler, L. T., Anton, E., Baker, D., et al. (1997) Impact of mutation, plasma protein binding and pharmacokinetics on clinical efficacy of the HIV-1 non nucleoside reverse transcriptase inhibitor, DMP 266, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28–October 1 [abstract I-115].
Joshi, A., Fiske, W. D., Benedek, I. H., White, S. J., Joseph, J. L., and Kornhauser, D. M. (1998) Lack of pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy volunteers, 5th Conference on Retroviruses and OpportunisticInfections, Chicago, IL, February 4–8 [abstract 348].
Graul, A., Rabasseda, X., and Castaner, J. (1998) Efavirenz, Drugs Future, 23, 133–141.
Mayers, D., Riddler, S., Stein, D., Bach, M., Havlir, D., and Kahn, J. (1996) A double blind pilot study to evaluate the antiviral activity, tolerability and pharmacokinetics of DMP 266 alone and in combination with indinavir, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15–18 [abstract LB8a].
Fiske, W. D., Benedek, I. H., Joseph, J. L., et al. (1998) Pharmacokinetics of efavirenz (EFV) and ritonavir (RTV) after multiple oral doses in healthy volunteers, 12th World AIDS Conference, Geneva, Switzerland, June 28–July 3 [abstract 42269].
Benedek, I. H., Joshi, A., Fiske, W. D., et al. (1998) Pharmacokinetic interaction between efavirenz (EFV) and rifampin (RIF) in healthy volunteers, 12th World AIDS Conference, Geneva, Switzerland, June 28–July 3 [abstract 42280].
Benedek, I. H., Joshi, A., Fiske, W. D., et al. (1998) Pharmacokinetic (PK) interaction studies with efavirenz (EFV) and the macrolide antibiotics azitromycin (AZM) and clarithromycin (CLR), 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4–8 [abstract 347].
Fiske, W. D., Benedek, I. H., White, S. J., Joseph, J. L., and Kornhauser, D. M. (1997) Pharmacokinetic interaction between DMP 266 and nelfinavir mesylate (NFV) in healthy volunteers, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28–October 1 [abstract I-174].
Fiske, W. D., Mayers, D., Wagner, K., et al. and the DMP 266 Development Team (1997) Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22–26 [abstract].
Fiske, W. D., Benedek, I. H., Joshi, A. S., Joseph, J. L., and Kornhauser, D. M. (1998) Summary of pharmacokinetic drug interactions studies with efavirenz, 36th Annual Meeting of the Infectious Disease Society of America, Denver, CO, November 12–15 [abstract 460].
Bristol-Myers Squibb Company (2002) Sustiva package insert, Bristol-Myers Squibb Co., Princeton, NJ.
Hendrix, C. W., Fiske, W. D., Fuchs, E. J., et al. (2000) Pharmacokinetics of the triple combination of saquinavir, ritonavir and efavirenz in HIV positive patients, 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30–February 2 [abstract].
Abbott Laboratories (2008) Kaletra package insert, Abbott Laboratories, North Chicago, IL.
Romero, D. L., Busso, M., Tan, C. K., et al. (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication, Proc. Natl. Acad. Sci. U.S.A., 88, 8806–8810.
Busso, M., Mian, A. M., Hahn, E. F., and Resnick, L. (1988) Nucleotide dimers suppress HIV expression in vitro, AIDS Res. Hum. Retroviruses, 4, 449–455.
Tan, C. K., Zhang, J., Li, Z. Y., Tarpley, W. G., Downey, K. M., and So, A. G. (1991) Functional characterization of RNA-dependent DNA polymerase and RNase H activities of a recombinant HIV reverse transcriptase, Biochemistry, 30, 2651–2655.
Freimuth, W. W. (1996) Delavurdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor, Adv. Exp. Med. Biol., 394, 279–289.
Esnouf, R. M., Ren, J., Hopkins, A. L., et al. (1997) Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor, Proc. Natl. Acad. Sci. U.S.A., 94, 3984–3989.
Althaus, I. W., Chou, J. J., Gonzales, A. J., et al. (1994) Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152S, Biochem. Pharmacol., 47, 2017–2028.
Dueweke, T. J., Poppe, S. M., Romero, D. L., et al. (1993) U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication, Antimicrob. Agents Chemother., 37, 1127–1131.
Conway, B. (2006) Delavirdine. In: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (Skowron, G. and Ogde, R., eds.), Humana Press, Totowa, NJ, pp. 375–400.
Demeter, L. M., Shafer, R. W., Meehan, P. M., et al. (2000) Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/I trial of delavirdine monotherapy (ACTG 260), Antimicrob. Agents Chemother., 44, 794–797.
Gerondelis, P., Archer, R. H., Palaniappan, C., et al. (1999) The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end and DNA 3′-end-directed RNase H activities, J. Virol., 73(7), 5803–5813.
Friedland, G. H., Pollard, R., Griffith, B., et al. (1999) Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team, J. Acquir. Immune Defic. Syndr., 21, 281–292.
Conway, B. (2000) Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine, Clin. Infect. Dis., 30(Suppl. 2), S130–S134.
Wood, R., Hawkins, D. A., Moyle, G., De Cain, W., Ingrosso, A., and Greenwald, C. (1999) Second placebo-controlled study in naïve individuals confirms the role of delavirdine in highly active antiretroviral, protease-sparing treatment, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31–February 4 [abstract 624].
Kuritzkes, D. R., Bassett, R. L., Johnson, V. A., et al. (2000) Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group Protocol 370, AIDS, 14, 1553–1561.
Smith, G. H., Boulassel, M. R., Klein, M, et al., (2004) Virulogic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1 infected patients, HIV Clin. Trials, 6, 63–72.
Gatell, J., Kuritzkes, D., and Green, S. (1999) Twice daily dosing of delavirdine in combination with nelfinavir, didanosine, and stavudine results in significant decreases in viral burden, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26–29 [abstract 520].
Conway, B., Chu, A., Tran, T., et al., for the 0081 Study Group (2001) A pilot study of combinations of delavirdine (DLV), zidovudine (ZDV), lamivudine (3TC), and saquinavir-SGC (Fortovase®, FTV) as initial antiretroviral therapy: virologic and pharmacokinetic considerations, 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4–8 [abstract 331].
Eron, J., Chu, A., Petersen, C., et al. (2001) 48 week efficacy of triple drug HAART containing delavirdine and reduced dose indinavir is comparable to HAART containing full dose indinavir, 1st IAS Conference on HIVPathogenesis and Treatment, Buenos Aires, Argentina, July 8–11 [abstract 232].
Bellman, P. C. (1998) Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed, AIDS, 12, 1333–1340.
Smith, D., Hales, G., Roth, N., et al. (2001) A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients, HIV Clin. Trials, 2, 97–107.
Blanco, J. L., Mallolas, J., Sarasa, M., et al. (2000) A pilot study of a twice daily (BID) combination of indinavir/delavirdine plus two nucleoside analogues for salvage therapy in HIV-1 infected patients, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17–20 [abstract 1543].
Baril, J. G., Lefebvre, E. A., Lalonde, R. G., Shafran, S. D., and Conway, B. (2003) Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients, Can. J. Infect. Dis., 14, 201–205.
Tran, J. Q., Gerber, J. G., and Kerr, B. M. (2001) Delavirdine: clinical pharmacokinetics and drug interactions, Clin. Pharmacokinet., 40, 207–226.
Cox, S. R., Schneck, D. W., Herman, B. D., et al. (1998) Delavirdine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers, 5th Conferences on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5 [abstract 345].
Morse, G. D., Fischl, M. A., Shelton, M. J., et al. (1997) Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection, Antimicrob. Agents Chemother., 41, 169–174.
Voorman, R. L., Maio, S. M., Hauer, M. J., Sanders, P. E., Payne, M. A., and Ackland, M. J. (1998) Metabolism of delavirdine, a human immunodeficiency virus type 1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A, Drug Metab. Dispos., 26, 631–639.
Freimuth, W. W. (1996) Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor, Adv. Exp. Med. Biol., 394, 279–289.
Gangar, M., Arias, G., O’Brian, J. G., and Kemper, C. A. (2000) Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine, Ann. Pharmacother., 34, 839–842.
Para, M., Slater, L., Daly, P., et al. (1999) Delavirdine in combination therapy has a favorable liver safety profile in HIV-1 patients, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26–29 [abstract 331].
Reisler, R., Liou, S., Servoos, J., et al. (2001) Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials, 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 8–11 [abstract 43].
Palmon, R., Koo, B. C., Shoultz, D. A., and Dieterich, D. T. (2002) Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors, J. Acquir. Immune Defic. Syndr., 29, 340–345.
Scott, L. J. and Perry, C. M. (2000) Delavirdine: a review of its use in HIV infection, Drugs, 60, 1411–1444.
Clevenbergh, P., Cua, E., Dam, E., et al. (2002) Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients, HIV Clin. Trials, 3(1), 36–44.
Nissley, D. V., Church, J. D., Guay, L. A., et al. (2006) Phenotypic NNRTI resistance and genetic diversity in drug-naive individuals, XV International HIV Drug Resistance Workshop, Sitges, Spain, June 13–17, abstract 138.
Paolucci, S., Baldani, F., Tinelli, M., et al. (2002) Q145M, a novel HIV-1 reverse transcriptase mutation conferring resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors, Antivir. Ther., 7(2), S35.
Harrigan, P. R., Salim, M., Stammers, D. K., et al. (2002) A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with non-nucleoside reverse transcriptase inhibitor resistance, J. Virol., 76(13), 6836–6840.
Kemp, S., Salim, M., Stammers, D., Wynhoven, B., Larder, B., and Harrigan, P. R. (2001) A mutation in HIV-1 RT at codon 318 (Y to F) confers high level NNRTI resistance in clinical samples, 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 16–19 [abstract 1762].
Huang, W., Parkin, N. T., Lie, Y. S., et al. (2000) A novel HIV-1 RT mutation (M230L) confers NNRTI resistance and dose-dependent stimulation of replication, Antivir. Ther., 5(Suppl. 3), S24–S25.
Little, S. J., Holte, S., Routy, J. P., et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV, N. Engl. J. Med., 347(6), 385–394.
Pilon, R., Sandstrom, P., Burchell, A., et al. (2002) Transmitted HIV-1 reverse transcriptase inhibitor resistance mutation stability in ART-naïve recent seroconverters: results of the polaris HIV seroconversion study, XIV International AIDS Conference, Barcelona, July 7–12 [abstract TuPeB4611].
Imrie, A., Carr, A., Duncombe, C., et al. (1996) Primary infection with zidovudine-resistant human immunodeficient virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study group, J. Infect. Dis., 174(1), 195–198.
Conant, M., Brown, S., Cohen, C., et al. (1999) An epidemiological prospective survey assessing the prevalence of HIV-1 drug resistance in 230 HIV-1-positive antiretroviral naïve patients from the USA, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26–29 [abstract 443].
Becker, M. I., Haubrich, R., Wesselman, C. W., et al. (2002) HIV-1 genotypic resistance in treatment-naïve subjects enrolled in an observational trial (GAIN), Antivir. Ther., 7(Suppl. 2), S134.
Huang, W., Wrin, T., Gamarnik, A., Beauchaine, J., Whitcomb, J. M., and Petropoulos, C. J. (2002) Reverse transcriptase mutations that confer non-nucleoside reverse transcriptase inhibitor resistance may also impair replication capacity, Antivir. Ther., 7(Suppl. 2), S60.
Soderberg, K., Thompson, M., and Alexander, L. (2002) Impaired in vitro fitness of nevirapine resistant HIV-1 mutants, 9th Conference on Retroviruses and Opportunistic Infections, Seattle WA, February 24–28 [abstract 577].
Archer, R. H., Dykes, C., Gerondeles, P., et al. (2000) Mutants of human immunodeficiency virus type 1 (HIV-1) reverse {transcriptase} resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture, J. Virol., 74(18), 8390–8401.
Whitcomb, J. M., Huang, W., Limoli, K., et al. (2002) Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates, AIDS, 16(15), F41–F47.
Das, K., Clark, A. D., Jr., Lewi, P. J., Heeres, J., et al. (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants, J. Med. Chem., 47(10), 2550–2560.
Ludovici, D. W., De Corte, B. L., Kukla, M. J., Ye, H., et al. (2001) Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues, Biorg. Med. Chem. Lett., 11(17), 2235–2239.
Lewi, P. J., de Jonge, M., Daeyaert, F., Koymans, L., et al. (2003) On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data, J. Comput. Aided Mol. Des., 17(2–4), 129–134.
Grossman, H. A., Hicks, C., Nadler, J., et al. (2005) Efficacy and tolerability of Tmc125 in HIV patients with NNRTI and PI resistance at 24 weeks: Tmc125-c223, 45th Interscience Conference of Antimicrobial Agents and Chemotherapy, Washington, D.C., December 16–19 [abstract H-416c].
Medscape—The continuing promise of TMC125, a second-generation NNRTI (http://www.medscape.com/viewarticle/429091).
Schöller, M., Kraft, M., Hoetelmans, R., et al. (2006) Significant decrease in TMC125 exposures when co-administered with tipranavir boosted with ritonavir in healthy subjects, 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5–8 [abstract 583].
Kukuda, T., M. Schöller-Gyüre, M., Peeters, M., Woodfall, B., et al. (2006) Pharmacokinetic interaction study with TMC125 and TMC114/RTV in HIV-negative volunteers, 16th International AIDS Conference, Toronto, Canada, August 13–18 [abstract TuPe0086].
Anderson, M. S., Kakuda, T. N., Miller, J. L., et al. (2007) Pharmacokinetic evaluation of non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 and integrase inhibitor (InSTI) raltegravir (RAL) in healthy subjects, 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22–25 [abstract TUPDB02].
Ramanathan, S., West, S., Kakuda, T. N., et al. (2007) Lack of clinically relevant drug interaction between ritonavir-boosted elvitegravir and TMC 125, 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20 [abstract H-1407].
Mills, A., Cahn, P., Grinsztejn, B., et al. (2007) DUET-1: 24 week results of a phase III randomised double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 612 treatment-experienced HIV-1 infected patients, 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment, and Prevention, Sydney, Australia, July 22–25 [abstract (late-breaker) WeSS204:1].
Katlama, C., Campbell, T., Clotet, B., et al. (2007) DUET-2: 24 week results of a phase III randomised double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 591 treatment-experienced HIV-1 infected patients, 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment, and Prevention, Sydney, Australia, July 22–25 [abstract (late-breaker) WeSS204:2].
Madruga, J. V., Cahn, P., Grinsztejn, B., et al. on behalf of the DUET-1 Study Group (2007) Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial, Lancet, 370(9581), 29–38.
Lazzarin, A., Campbell, T., Clotet, B., et al. on behalf of the DUET-2 Study Group (2007) Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial, Lancet, 370(9581), 39–48.
Cohen, C., Steinhart, C. R., and Ward, D. J. (2006) Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223, XVIth International AIDS Conference, Toronto, Canada, August 13–18 [abstract TUPE0061].
Jansen, P. A. J., Lewi, P. J., Arnold, E., et al. (2005) In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl] amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine), J. Med. Chem., 48(6), 1901–1909.
Pozniak, A., Morales-Ramirez, J., Mohapi, L., et al. (2007) 48-week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-naïve patients, 14th Conference of Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25–28 [abstract 144LB].
Ruxrungtham, K., Bellos, N., Morales-Ramirez, J., et al. (2007) The metabolic profile of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Sydney. Australia, July 22–25 [abstract TUAB105].
Kashman, Y., Gustafson, K. R., Fuller, R. W., et al. (1992) The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum, J. Med. Chem., 35, 2735–2743.
Boyer, P. L., Currens, M. J., McMahon, J. B., Boyd, M. R., and Hughes, S. H. J. (1993) Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase, Virology, 67, 2412–2420.
Hizi, A., Tal, R., Shaharabany, M., Currens, M. J., Boyd, M. R., Hughes, S. B., and McMahon, J. B. (1993) Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors, Antimicrob. Agents Ther., 37, 1037–1042.
Cardellina, J. H., II, Bokesch, H. R., McKee, T. C., and Boyd, M. R. (1995) Resolution and comparative anti-HIV evaluation of the enantiomers of calanolides A and B, BioMed. Chem. Lett., 5, 1011–1014.
Galinis, D. L., Fuller, R. W., McKee, T. C., Cardellina, J. H., II, Gulakowski, R. J., McMahon, J. B., and Boyd, M. R. (1996) Structure-activity modifications of the HIV-1 inhibitors (+)-calanolide A and (−)-calanolide B, J. Med. Chem., 39, 4507–4510.
Currens, M. J., Gulakowski, R. J., Mariner, J. M., Moran, R. A., Buckheit, R. W., et al. (1996) Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1, J. Pharmacol. Exp. Ther., 279, 645–651.
Currens, M. J., Mariner, J. M., McMahon, J. B., and Boyd, M. R. (1996) Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A, J. Pharmacol. Exp. Ther., 279, 652–661.
McKee, T. C., Covington, C. D., Fuller, R. W., et al. (1998) Pyranocoumarins from tropical species of the genus Calophyllum: a chemotaxonomic study of extracts in the National Cancer Institute collection, J. Nat. Prod., 61, 1252–1256.
Kashman, Y., Gustafson, K. R., Fuller, R. W., et al. (1992) The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum, J. Med. Chem., 35(15), 2735–2743.
Khilevich, A., Mar, A., Flavin, M. T., Rizzo, J. D., et al. (1996) Synthesis of (+)-calanolide A, an anti-HIV agent, via enzyme-catalyzed resolution of the aldol products, Tetrahedron: Asymmetry, 7(11), 3315–3326.
Chenera, B., West, M. L., Finkelstein, J. A., and Dreyer, G. B. (1993) Total synthesis of (+)-calanolide A, a non-nucleoside inhibitor of HIV reverse transcriptase, J. Org. Chem., 58, 5605–5606.
Creagh, T., Ruckle, J. L., Tolbert, D. T., Giltner, J., Eiznhamer, D. A., Dutta, B., Flavin, M. T., and Xu, Z.-Q. (2001) Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects, Antimicrob. Agents Chemother., 45(5), 1379–1386.
Buckheit, R. W., Jr., Russell, J. D., Xu, Z. Q., and Flavin, M. (2000) Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication, Antivir. Chem. Chemother., 11(5), 321–327.
Kohl, N. R., Emini, E. A., Schleif, W. A., et al. (1988) Active human immunodeficiency virus protease is required for viral infectivity, Proc. Natl. Acad. Sci. U.S.A., 85, 4686–4690.
Peng, C., Ho, B. K., Chang, T. W., and Chang, N. T. (1989) Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity, J. Virol., 63, 2550.
Gottlinger, H. G., Sodroski, J. G., and Haseltine, W. A. (1989) Role of the capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1, Proc. Natl. Acad. Sci. U.S.A., 86, 5781–5789.
Wlodawer, A. and Erickson, J. W. (1993) Structure-based inhibitors of HIV-1 protease, Rev. Biochem., 62, 543–585.
Bhat, T. N., Baldwin, E. T., Liu, B., Cheng, Y.-S. E., and Erickson, J. W. (1994) Crystal structure of a tethered dimer of HIV-1 proteinase complexed with an inhibitor, Nat. Struct. Biol., 1, 552–556.
Pearl, L. H. and Taylor, W. R. (1987) A structural model for the retroviral proteases, Nature, 329, 351–354.
Flexner, C. (1998) HIV-protease inhibitors, N. Engl. J. Med., 338(18), 1281–1291.
Kramer, R. A., Schaber, M. D., Skalka, A. M., Ganguly, K., Wong-Staal, F., and Reddy, E. P. (1986) HTLV-III gag protein is processed in yeast cells by the virus pol-protease, Science, 231, 1580–1584.
Graves, M. C., Lim, J. J., Heimer, E. P., and Kramer, R. A. (1988) An 11-kDa form of human immunodeficiency virus protease expressed in Escherichia coli is sufficient for enzymatic activity, Proc. Natl. Acad. Sci. U.S.A., 85, 2449–2453.
Le Grice, S. F. J., Mills, J., and Mous, J. (1988) Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation, EMBO J., 7, 2547–2553.
Henderson, L. E., Bowers, M. A., Sowder, R. C., II, et al. (1992) Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences, J. Virol., 66, 1856–1865.
Flexner, C., Broyles, S. S., Earl, P., Chakrabarti, S., and Moss. B. (1988) Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses, Virology, 166, 339–349.
Karacostas, V., Nagashima, K., Gonda, M. A., and Moss, B. (1989) Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector, Proc. Natl. Acad. Sci. U.S.A., 86, 8964–8967.
Debouk, C. (1992) The HIV-1 protease as a therapeutic target for AIDS, AIDS Res. Hum. Retroviruses, 8, 153–164.
Overton, H. A., McMillan, D. J., Gridley, S. J., Brenner, J., Redshaw, S., and Mills, J. S. (1990) Effect of two novel inhibitors of the human immunodeficiency virus protease on the maturation of the HIV gag and gag-pol polyproteins, Virology, 179, 508–511.
Tomaszek, T. A., Magaard, V. W., Bryan, H. G., Moore, M. L., and Meek, T. D. (1990) Chromophoric peptide substrates for the spectrophotometric assay of HIV-1 protease, Biochem. Biophys. Res. Commun., 168, 274–280.
Hyland, L. J., Dayton, B. D., Moore, M. L., Shu, A. Y., Heys, J. R., and Meek, T. D. (1990) A radiometric assay for HIV-1 protease, Anal. Biochem., 188, 408.
Phylip, L. H., Richards, A. D., Kay, J., et al. (1990) Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases, Biochem. Biophys. Res. Commun., 171, 439.
Tamburini, P. P., Dreyer, R. N., Hansen, J., et al. (1990) A fluorometric assay for HIV-protease activity using high-performance liquid chromatography, Anal. Biochem., 186, 363.
Richards, A. D., Phylip, L. H., Farmeri, W. G., et al. (1990) Sensitive, soluble chromogenic substrates for HIV-1 proteinase, J. Biol. Chem., 265, 7733–7736.
Matayoshi, E. D., Wang, G. T., Krafft, G. A., and Erickson, J. (1990) Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer, Science, 247, 954–958.
Billich, A. and Winkler, G. (1990) Colorimetric assay of HIV-1 proteinase suitable for high-capacity screening, Peptide Res., 3, 274.
Roberts, N. A., Martin, J. A., Kinchington, D., et al. (1990) Rational design of peptide-based HIV proteinase inhibitors, Science, 248, 358–361.
Meek, T. D., Lambert, D. M., Dreyer, G. B., et al. (1990) Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues, Nature, 343, 90–92.
Rich, D. H., Green, J., Toth, M. V., Marshall, G. R., and Kent, S. B. (1990) Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease, J. Med. Chem., 33, 1285–1288.
McQuade, T. J., Tomasselli, A. G., Liu, L., et al. (1990) A synthetic HIV protease inhibitor with antiviral activity arrests HIV-like particle maturation, Science, 247, 454–456.
Ashorn, P., McQuade, T. J., Thaisrivongs, S., Tomasselli, A. G., Tarpley, W. G., and Moss, B. (1990) An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection, Proc. Natl. Acad. Sci U.S.A., 87, 7472–7476.
Dreyer, G. B., Metcalf, B. W., Tomaszek, T. A., et al. (1989) Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors, Proc. Natl. Acad. Sci. U.S.A., 86, 9752–9755.
Kempf, D. J., Norbeck, D. W., Codavoli, L., et al. (1990) Structure-based, C2 symmetric inhibitors of HIV protease, J. Med. Chem., 33, 2687–2689.
Chrusciel, R. A. and Romines, K. R. (1997) Recent developments in HIV protease inhibitor research, Exp. Opin. Ther. Patents, 7(2), 111–121.
Lea, A. P. and Faulds, D. (1996) Ritonavir, Drugs, 52(4), 541–546.
Erickson, J., Neidhart, D. J., Vandrie, J., et al. (1990), Design, activity and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease, Science, 249, 527–533.
Bryant, M. L., Heuckeroth, R. O., Kimata, J. T., Ratner, L., and Gordon, J. I. (1989) Replication of human immunodeficiency virus 1 and moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid, Proc. Natl. Acad. Sci. U.S.A., 86, 8655–8659.
Monini, P., Sgarari, C., Barillari, G., and Ensoli, B. (2003) HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumor activity, J. Antimicrob. Chemother., 51, 207–211.
Deeks, S. G., Smith, M., Holodniy, M., and Kahn, J. O. (1997) HIV-1 protease inhibitors. A review for clinicians, J. Am. Med. Assoc., 277(2), 145–153.
Fitzimmons, M. E. and Collins, J. M. (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4; potential contribution to high first-pass metabolism, Drug Metab. Dispos., 25, 256–266.
Kumar, G. N., Rodrigues, A. D., Buko, A. M., and Denissen, J. F. (1996) Cytochrome (ABT-538) in human liver microsomes, J. Pharmacol. Ther., 277, 423–431 [erratum: J. Pharmacol. Ther., 281, 1506, (1997)].
Chiba, M., Hensleigh, M., Nishime, J. A., Balani, S. K., and Lin, J. H. (1996) Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor, Drug Metab. Dispos., 24, 307–314.
Piscitelli, S. C., Flexner, C., Minor, J. R., Polis, M. A., and Masur, H. (1996) Drug interactions in patients infected with human immunodeficiency virus, Clin. Infect. Dis., 23, 685–693.
Roberts, A. D., Muesing, A., Parenti, D. M., Hsia, J., Wasserman, A. G., and Simon, G. L. (1999) Alteration of serum lipids and lipoproteins with indinavir in HIV-infected patients, Clin. Infect. Dis., 29, 441–443.
Graham, N. M. (2000) Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review, J. Acquir. Immune Defic. Syndr., 25(Suppl. 1), S4–S11.
Powderly, W. G. (2002) Long-term exposure to lifelong therapies, J. Acquir. Immune Defic. Syndr., 29(Suppl. 1), S28–S40.
White, A. J. (2001) Mitochondrial toxicity and HIV disease, Sex. Transm. Infect., 77, 158–173.
Walker, U. A., Setzer, B., and Venhoff, N. (2002) Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors, AIDS, 16(16), 2165–2173.
Boshoff, C. and Weiss, R. (2002) AIDS-related malignancies, Nat. Rev. Cancer, 2, 373–382.
Sgadari, C., Barillari, G., Toschi, E., Carlei, D., Bacigalupo, I., Baccarini, S., et al. (2002) HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma, Nat. Med., 8, 225–232.
International Collaboration on HIV and Cancer (2000) Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults, J. Natl. Cancer Inst., 92, 1823–1830.
Cattelan, A. M., Calabro, M. L., Aversa, S. M., Zanchetta, M., Meneghetti, F., De Rossi, A., et al. (1999) Regression of AIDS-related Kaposi’s sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome, Eur. J. Cancer, 35, 1809–1815.
Fischle, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., et al. (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex, N. Engl. J. Med., 317, 185–191.
Zucker, S. D., Qin, X., Rouster, S. D., Yu, F., Green, R. M., Keshavan, P., et al. (2001) Mechanism of indinavir-induced hyperbilirubinemia, Proc. Natl. Acad. Sci. U.S.A., 98, 12671–12676.
Liang, J. S., Distler, O., Cooper, D. A., Jamil, H., Deckelbaum, R. J., Ginsberg, H. N., et al. (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia, Nat. Med., 7, 1327–1331.
Murata, H., Hruz, P. W., and Mueckler, M. (2002) Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations, AIDS, 16, 859–863.
Jain, R. G. and Lenhard, J. M. (2002) Select HIV protease inhibitors alter bone and fat metabolism ex vivo, J. Biochem. Chem., 277, 19247–19250.
Phenix, B. N., Lum, J. J., Nie, Z., Sanchez-Dardon, J., and Badley, A. D. (2001) Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss, Blood, 98, 1078–1085.
Chavan, S., Kodoth, S., Pahwa, R., and Pahwa, S. (2001) The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals, Blood, 98, 383–389.
Pati, S., Pelser, C. B., Dufraine, J., Bryant, J. L., Reitz, M. S., and Weichold, F. F. (2002) Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma, Blood, 99, 3771–3779.
Andre, P., Groettrup, M., Klenerman, P., de Giuli, R., Booth, B. L., Jr., Cerundolo, V., et al. (1998) An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses, Proc. Natl. Acad. Sci. U.S.A., 95, 13120–13124.
Tovo, P. A. (2000) Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects, AIDS, 14, 743–744.
Gruber, A., Wheat, J. C., Kuhen, K. L., Looney, D. J., and Wong-Staal, F. (2001) Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function, J. Biol. Chem., 276, 47840–47843.
Ensoli, B., Gendelman, R., Markham, P., Fiorelli, V., Colombini, S., Raffeld, M., et al. (1994) Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi’s sarcoma, Nature, 371, 674–680.
Ensoli, B., Sturzl, M., and Monini, P. (2001) Reactivation and role of HHV-8 in Kaposi’s sarcoma initiation, Adv. Cancer Res., 81, 161–200.
Wei, X., Ghosh, S. K., Taylor, M. E., et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection, Nature, 373, 117–122.
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., and Markowitz, M. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, Nature, 373, 123–126.
Danner, S. A., Carr, A., Leonard, J. M., et al. (1995) A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease, N. Engl. J. Med., 333, 1528–1533.
Markowitz, M., Saag, M., Powderly, W. G., et al. (1995) A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection, N. Engl. J. Med., 333, 1534–1539.
Hammer, S. M., Squires, K. E., Hughes, M. D., et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less, N. Engl. J. Med., 337, 725–733.
Gulick, R. M., Mellors, J. W., Havlir, D., et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral activity, N. Engl. J. Med., 337, 734–739.
Noble, S. and Goa, K. L. (2000) Amprenavir: a review of its potential in patients with HIV infection [drug evaluation], Drugs, 60(6), 1383–1410.
Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., et al. (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel, J. Am. Med. Assoc., 283(3), 381–390.
BHIVA Writing Committee on Behalf of the BHIVA Executive Committee. (2000) British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy [online]. British HIV Association (http://www.aidsmap.com/bhiva/bhivagd1299.htm).
Moyle, G. J. and Gazzard, B. G. (1999) A risk-benefit assessment of HIV protease inhibitors, Drug Safety, 20, 299–321.
Panel on Clinical Practices for Treatment of HIV Infection (2000) Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. U.S. Department of Health and Human Services (http://www.hivatis.org/guidelines/adult/text/).
Steigbigel, R. T., Berry, P., Mellors, J., et al. (1996) Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK 639) at escalating doses, 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28–February 1 [abstract 146].
Moyle, G. L., Youle, M., Higgs, C., et al. (1996) Extended follow-up of the safety and activity of Agouron’s HIV protease inhibitor AG1343 (Viracept) in virological responders from the UK phase I/II dose finding study, 11th International Conference on AIDS, Vancouver, British Columbia, July 7–12 [abstract Mo.B.173].
Schooley, R. T. (1996) Preliminary data on the safety and antiviral efficacy of the novel protease inhibitor 141W94 in HIV-infected patients with 150 to 400 CD4+ cells/mm3, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15–18 [addendum: abstract].
Schapiro, J. M., Winters, M. A., Stewart, F., et al. (1996) The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients, Ann. Intern. Med., 124, 1039–1050.
Condra, J. H., Schleif, W. A., Blahy, O. M., et al. (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors, Nature, 374, 569–571.
Murphy, R., El-Sader, W., Cheung, T., et al. (1998) Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 study, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5 [abstract 181].
Moore, R. D., Keruly, J. C., and Chaisson, R. E. (1998) Decline in CMV and other opportunistic diseases with combination antiretroviral therapy, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5 [abstract 184].
McCollum, M., Klaus, B., La Rue, R., et al. (1998) HAART reduced overall costs of HIV care at DVAMC, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5 [abstract 200].
Keisher, P., Kvanh, M., Turner, D., et al. (1998) Decreased hospital utilization and costs are associated with protease inhibitor therapy but not nucleoside therapy, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5 [abstract 204].
Paul, S., Ziecheck, W., Gilgert, H. M., et al. (1998) Impact of HAART on rates and types of hospitalization at a New York City hospital, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5 [abstract 205].
Bermudes, R. A., Toerner, J. G., Mathews, W. C., et al. (1997) The effect of initiating protease inhibitor therapy on hospitalization rates and the quality of life in HIV+ patients, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28–October 1 [abstract I-182].
Hogg, R. S., Heath, K. V., Yip, B., et al. (1997) Improved survival among HIV-infected individuals: the potential impact of newer antiretroviral therapy strategies, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28–October 1 [abstract I-198].
Palella, F. J., Delaney, K. M., Moorman, A. C., et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, N. Engl. J. Med., 338, 853–860.
Cohen, C., Sun, E., Cameron, W., et al (1996) Ritonavir-saquinavir combination treatment in HIV-infected patients, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15–18 [abstract Th.b.934].
Cameron, D. W., Japour, A. J., Xu, A., et al. (1999) Ritonavir and saquinavir combination therapy for the treatment of HIV infection, AIDS, 13(2), 213–224.
Condra, J. H., Schleif, W. A., Blahy, O. M., et al. (1995), In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors, Nature, 374, 569–571.
Molla, M., Korneyeva, M., Gao, Q., et al. (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir, Nat. Med., 2, 760–766.
Schinazi, R. F., Larder, B. A., and Mellors, J. W. (1996) Mutations in retroviral genes associated with drug resistance, Int. Antiviral News, 4, 95–107.
Schapiro, J. M., Winters, M. A., Vierra, M., et al. (1996) Causes of long-term efficacy and/or drug failure in protease inhibitor monotherapy, 11th International Conference on AIDS, Vancouver, B.C., July 7–12 [abstract Mo.B.414].
Romano, L., Venturi, G., Giomi, S., Pippi, L., Valensin, P. E., and Zazzi, M. (2002) Development and resistance to protease inhibitors in HIV-1–-infected adults under triple-drug therapy in clinical practice, J. Med. Virol., 66(2), 143–150.
el-Farrash, M. A., Kuroda, M. J., Kitazaki, T., et al. (1994) Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor, J. Virol., 68, 233–239.
Flexner, C. (1996) Pharmacokinetics and pharmacodynamics of HIV protease inhibitors, Infect. Med., 13(Suppl.), F16–F23.
Condra, J. H., Holder, D. J., Schleif, W. A., et al. (1996) Bi-directional inhibition of HIV-1 drug resistance selection by combination therapy with indinavir and reverse transcriptase inhibitors, 11th International Conference on AIDS, Vancouver, B.C., July 7–12 [abstract Th.B.932].
Figgitt, D. P. and Plosker, G. L. (2000) Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection, Drugs, 60(2), 481–516.
Plosker, G. L. and Scott, L. J. (2003) Saquinavir: a review of its use in boosted regimens for treating HIV infection, Drugs, 63(12), 1299–1324.
Lopez-Cortes, L. F., Ruiz-Valderas, R., Rivero, A., Camacho, A., Marquez-Solero, M., Santos, J., Rodriguez-Banos, J., and Ocampo, A. (2007) Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy, Ther. Drug Monit., 29(2), 171–176.
Winston, A., Back, D., Fletcher, C., et al. (2006) Effect of omeprasole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers, AIDS, 20(10), 1401–1406.
Collazos, J., Martínez, E., Mayo, J., and Blanco, M.-S. (2000) Effect of ketoconazole on plasma concentrations of saquinavir, J. Antimicrob. Chemother., 46, 151–153.
Hendrix, C. W., Fiske, W. D., Fuchs, E. J., Redpath, E. C., Stevenson, D. L., Benedek, I. H., and Kornhauser, D. M. (2000) Pharmacokinetics of the triple combination of saquinavir, ritonavir, and efavirenz in HIV-positive patients, 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30–February 2 [abstract 79].
Roche Laboratories (2005) Important drug interaction warning: drug-induced hepatitis with marked transaminase elevation has been observed in healthy volunteers receiving rifampin 600 mg once daily in combination with ritonavir 100 mg/saquinavir 100 mg twice daily (ritonavir boosted saquinavir), Roche Laboratories, Nutley, NJ.
Roche Laboratories (1997) FortovaseTM (saquinavir) soft gelatin capsules. Product information (http://www.rocheusa.com/products/invirase/).
Huisman, M. T., Smit, J. W., Wiltshire, H. R., et al. (2001) P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir, Mol. Pharmacol., 59(4), 806–813.
Boyd, M. A., Siangphoe, U., Ruxrungtham, K., Reiss, P., Apicha Mahanonthar, A., et al. (2006) The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity, J. Antimicrob. Chemother., 7(6), 1161–1167.
Kempf, D. J., Marsh, K. C., Kumar, G., et al. (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir, Anti-microb. Agents Chemother., 41, 654–660.
Gulick, R. M., Meibohm, A., Havlir, D., et al. (2003) Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine, AIDS, 17, 2345–2349.
Kopp, J. B., Miller, K. D., Mican, J. A., et al. (1997) Crystalluria and urinary tract abnormalities associated with indinavir, Ann. Intern. Med., 127, 119–125.
Boubaker, K., Sudre, P., Bally, F., et al. (1998) Changes in renal function associated with indinavir, AIDS, 12, F249–F54.
Berns, J. S., Cohen, R. M., Silverman, M., et al. (1997) Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases, Am. J. Kidney Dis., 30, 558–560.
Vigano, A., Rombola, G., Barbiano di Belgioioso, G., et al. (1998) Subtle occurrence of indinavir-induced acute renal insufficiency, AIDS, 12, 954–955.
Kohl, N. E., Emini, E. A., Schleif, W. A., et al. (1988) Active human immunodeficiency virus protease is required for viral infectivity, Proc. Natl. Acad. Sci. U.S.A., 85, 4686–4690.
Condra, J. H., Gabryelski, W. A., Blahy, O. M., et al. (1996) In vivo evolution of resistance to the HIV-1 protease inhibitor indinavir, 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28–February 1, [abstract 88].
Mellors, J., Steigbigel, R., Gulick, R., et al. (1995) Antiretroviral activity of the oral protease inhibitor, MK-639, in p24-antigenemic, HIV-1 infected patients with < 500 CD4/mm3, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17–20 [abstract 235].
Vacca, J. P., Dorsey, B. D., Schleif, W. A., et al. (1994) L-735,524: an orally bioavailable human immunodeficiency virus type1protease inhibitor, Proc. Natl. Acad. Sci. U.S.A., 91, 4096–4100.
Condra, J. H., Schleif, W. A., Blahy, O. M., et al. (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors, Nature, 374, 569–571.
Roberts, N. A., Race, E., Tomlinson, P., Gilbert, S., and Duncan, I. B. (1995) Resistance and cross resistance issues: studies with saquinavir, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17–20 [abstract 254].
Dykes, C., Najjar, J., Bosch, R. J., Wantman, M., et al. (2004) Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine, J. Infect. Dis., 189, 1091–1096.
Stein, D., Drusano, G., Steigbigel, R., et al. (1997) Two year follow-up of patients treated with indinavir 800 mg q8h, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22–26 [abstract 195].
Hupfer, M., Wagels, T., Kahlert, C., Bueche, D., Fierz, W., Walker, U., and Vernazza, P. (2004) Ritonavir boosted indinavir treatment as a simplified maintenance “mono”-therapy for HIV infection, AIDS, 18(6), 955–957.
Havlir, D. V., Marschner, I. C., Hirsch, M. S., Collier, A. C., Tebas, P., Bassett, R. L., et al. (1998) Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy, N. Engl. J. Med., 39, 1261–1268.
Moyle, G. (2000) Use of HIV protease inhibitors as pharmacoenhancers, AIDS Reader, 11, 87–98.
Peytavin, G., Flandre, P., Morand-Joubert, L., Lamotte, C., {Launay,} O., Gerard, L., Izard, S., Levy, C., Joly, V., Aboulker, J. P., Farinotti, R., and Yeni, P. (2003) Efficacy and safety related to indinavir and nevirapine plasma concentrations in a randomized controlled trial comparing indinavir and nevirapine versus indinavir containing regimen in HIV-1 infected patients (Trianon-ANRS081 Study), Antivir. Ther., 8(Suppl. 1), abstract 842.
Haas, D. W., Fessel, W. J., Delapenha, R. A., et al. (2001) Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial, J. Infect. Dis., 18, 392–400.
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults, N. Engl. J. Med., 34, 1865–1873.
Aarnoutse, R. E., Grintjes, K. J. T., Telgt, D., et al. (2002) The influence of efavirenz on the pharmacokinetics of a twice daily indinavir/ritonavir (800/100 mg) combination in healthy volunteers, Clin. Pharmacol. Ther., 71, 57–67.
Boyd, M. A., Aarnoutse, R. E., Ruxrungtham, K., Stek, M., van Heeswijk, R. P. G., Lange, J. M. A., Cooper, D. A., Phanuphak, P., and Burger, D. M. (2000) Pharmacokinetics of indinavir/ritonavir (88/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects, J. Acquir. Immune Defic. Syndr., 34(2), 134–139.
Boyd, M. A., Carr, A., Ruxrungtham, K., Srasuebkul, P., Bien, D., Law, M., Wangsuphachart, S., Krisanachinda, A., et al. (2004) Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz, J. Infect. Dis., 194, 642–650.
Cattelan, A. M., Trevenzoli, M., Naso, A., Meneghetti, F., and Cadrobbi, P. (2000) Severe hypertension and renal atrophy associated with indinavir, Clin. Infect. Dis., 30, 619–621.
Cattelan, A. M., Trevenzoli, M., Sasset, L., Rinaldi, L., Balasso, V., and Cadrobbi, P. (2001) Indinavir and systemic hypertension [Research Letters], AIDS, 15(6), 805–807.
Piscitelli, S. C., Burstein, A. H., Chaitt, D., Alfaro, R. M., and Falloon, J. (2000) Indinavir concentrations and St. John’s wort, Lancet, 355(9203), 547–548 [erratum: Lancet, 357(9263), 1210 (2001)].
Dieleman, J., Gyssens, I. C., van der Ende, M. E., de Marie, S., and Burger, D. M. (1998) Urologic complaints in relation to indinavir plasma levels in HIV-infected patients, XIIth Conference on AIDS, Geneva, Switzerland, June 28–July 3 [abstract 12372]
Familaro, G., Di Toro, S., Moretti, S., and De Simone, C. (2000) Symptomatic crystalluria associated with indinavir, Ann. Pharmacother., 34(12), 1414–1418.
Trainor, L. D., Steinberg, J. P., Austin, G. W., and Solomon, H. M. (1998) Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity, Arch. Pathol. Lab. Med., 122, 256–259.
Kohan, A. D., Armenakas, N. A., and Fracchia, J. A. (1999) Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus, J. Urol., 161(6), 1765–1768.
Brodie, S. B., Keller, J. K., Ewenstein, B. M., et al. (1998) Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients, AIDS, 12, 2433–2437.
Tashima, K. T., Horowitz, J. D., and Rosen, S. (1997) Indinavir nephropathy, N. Eng. J. Med., 336, 138–140.
Hanabusa, H., Tagami, H., and Hataya, H. (1999) Renal atrophy associated with long-term treatment with indinavir, N. Engl. J. Med., 340, 392–393.
Balani, S. K., Ariso, B. H., and Mathai, L. (1995) Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine, Drug Metab. Dispos., 23, 266–270.
Lin, J. H., Chen, I.-W., Vastag, K. J., et al. (2005) pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs, Drug Metab. Dispos., 23, 730–735.
Pai, V. B. and Nahata, M. C. (1999) Nelfinavir mesylate: a protease inhibitor, Ann. Pharmacother., 33, 325–339.
Bardsley-Elliot, A. and Plosker, G. L. (2000) Nelfinavir: an update on its use in HIV infection, Drugs, 59, 581–620.
Gathe, J., Jr., Burkhardt, B., Hawley, P., et al. (1996) A randomized phase II study of viracept, a novel HIV protease inhibitor, used in combination with stavudine (d4T) vs. stavudine (d4T) alone, XIth International Conference on AIDS, Vancouver, British Columbia, July 7–12 [abstract Mo.B.413].
Pedneault, L., Elion, R., Adler, M., et al. (1997) Stavudine (d4T), didanosine (ddI), and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22–26 [abstract 241].
Conant, M., Markowitz, M., Hurley, A., et al. (1996) A randomized phase II dose range-finding study of the HIV protease inhibitor viracept as monotherapy in HIV-positive patients, XIth International Conference on AIDS, Vancouver, British Columbia, July 7–12 [abstract Tu.B.2129].
Markowitz, M., Cao, Y., Hurley, A., et al. (1996) Triple therapy with AZT an 3TC in combination with nelfinavir mesylate in 12 antiretroviral-naïve subjects chronically infected with HIV-1, XIth International Conference on AIDS, Vancouver, British Columbia, July 7–12 [abstract LB.B.6031].
Saag, M., Knowles, M., Chang, Y., et al. (1997) Durable effect of viracept (nelfinavir mesylate, NFV) in triple combination therapy, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28–October 1 [abstract I-101].
Tebas, P., Patick, A., Kane, E. M., Klebert, M. K., Simpson, J. H., et al. (1999) Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir, AIDS, 13, F23–F28.
Albrecht, M. A., Bosch, R. J., Hammer, S. M., Liou, S. H., Kessler, H., Para, M. F., Eron, J., Valdez, H., Dehlinger, M., Katzenstein, D. A., and the AIDS Clinical Trials Group 364 Study Team (2001) Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection, N. Engl. J. Med., 345(6), 398–407.
Moyle, G., Pozniak, A., Opravil, M., Clumeck, N., DelFraissy, J. F., Johnson, M., Pelgrom, J., Reynes, J., Vittecoq, D., DeLora, P., Salgo, M., and Duff, F. (2000) The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe, J. Acquir. Immune Defic. Syndr., 23(2), 128–137.
Hammer, S. M., Bassett, R., Squires, K. E., Fischl, M. A., Demeter, L. M., Currier, J. S., Mellors, J. W., Morse, G. D., Eron, J. J., Santana, J. L., DeGruttola, V. and the ACTG 372B/D Study Team (2003) A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir, Antivir. Ther., 8(6), 507–518.
Gonzalez-Olivieri, L. M., Brindeiro, R., Soares, M., Pereira, H., Santana, R., Abreu, C., and Tanuri, A. (2004) Impact of nelfinavir-resistance mutations on the human immunodeficiency virus type 1 with subtype B and C proteases, XVth International Conference on AIDS, Bangkok, Thailand, July 11–16 [abstract WePeB5704].
Agouron Pharmaceuticals (1997) Viracept (nelfinavir mesylate) tablets and oral powder product monograph (package insert), Agouron Pharmaceuticals, La Jolla, CA.
Gathe, J., Burkhardt, B., Hawley, P., et al. (1996) A randomized phase II study of viracept, a novel HIV protease inhibitor, used in combination with stavudine vs. stavudine alone, 11th International Conference on AIDS, Vancouver, British Columbia, July 7–12 [abstract Mo.B. 413].
Michelet, C., Bellissant, E., Ruffault, A., et al. (1999) Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine, Clin. Pharmacol. Ther., 65, 661–671.
Domingo, E., Escarmis, C., Sevilla, N., et al. (1996) Basic concepts in RNA virus evolution, FASEB J., 10, 859–864.
Coffin, J. M. (1992) Genetic diversity and evolution of retroviruses, Curr. Top. Microbiol. Immunol., 176, 143–164
Nijhuis, M., Boucher, C. A. B., Schipper, P., Leitner, T., Schuurman, R., and Albert, J. (1998) Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy, Proc. Natl. Acad. Sci. U.S.A., 95(24), 14441–14446.
Abbott Pharmaceuticals (1999) Norvir (ritonavir) package insert. Abbott Pharmaceuticals, Abbott Park, IL.
Hoen, B., Harzic, M., Fleury, H. F., et al. (1997) ARNS053 trial of zidovudine (ZDV), lamivudine (3TC), and ritonavir combination in patients with symptomatic primary HIV-1 infection: preliminary results, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22–26 [abstract 232].
Saimot, A. G., Landman, R., Damond, F., et al. (1997) Ritonavir, stavudine (d4T), didanosine (ddI) as triple combination treatment in antiretroviral-naïve patients, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22–26 [abstract 246].
Markowitz, M., Saag, M., Powderly, W. G., et al. (1995) Preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection, N. Engl. J. Med., 328, 1534–1539.
Danner, S. A., Carr, A., Leonard, J. M., et al. (1995) A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease, N. Engl. J. Med., 328, 1528–1533.
Justesen, U. S., Hansen, I. M., Andersen, A. B., et al. (2005) The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1250 mg twice-daily regimen in HIV-infected patients, HIV Medicine, 6, 334–340.
Abbott Laboratories (1997) Norvir (ritonavir) capsule product monograph (package insert), Abbott Laboratories, North Chicago, IL.
Eron, J., Jr., Yeni, P., Gathe, J., Jr., et al. (2006) The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial, Lancet, 368, 476–482.
De Pasquale, M. P., Murphy, R., Kuritzkes, D., Martinez-Picado, J., Sommadossi, J. P., Gulick, R., Smeaton, L., DeGruttola, V., Caliendo, A. M., Sutton, L., Savara, A., and D’Aquila, R. T. (1998) Resistance during early virologic rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG 347, Antivir. Ther., 3(Suppl. 1), 50–51 [abstract 71].
Descamps, D., Masquelier, B., Mamet, J. P., Calvez, C., Ruffault, A., Telles, F., Goetschel, A., Girard, P. M., Brun-Vezinet, F., and Costagliola, D. (2001) A genotypic sensitivity score for amprenavir based genotype at baseline and virological response, Antivir. Ther., 6, 103.
Falloon, J., Piscitelli, S., Vogel, S., Sadler, B., Mitsuya, H., Kavlick, M. F., Yoshimura, K., Rogers, M., LaFon, S., Manion, D. J., Lane, H. C., and Masur, H. (2000) Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity, Clin. Infect. Dis., 30, 313–318.
Klein, A., Maguire, M., Paterson, D., Nacci, P., Mustafa, N., Yeo, J., Snowden, W., and Kleim, J. P. (2000) Virological response to amprenavir combination therapy in PI-experienced paediatric patients: association with distinct baseline HIV-1 protease variants–-study PROAB3004, Antivir. Ther., 5(Suppl. 2), 4 [abstract].
Maguire, M., MacManus, S., Griffin, P., Guinea, C., Harris, W., Richard, N., Wolfram, J., Tisdale, M., Snowden, W., and Klein, J.-P. (2001) Interaction of HIV-1 protease and gag gene mutations in response to amprenavir-selective pressure exerted in amprenavir-treated subjects—contribution of gag p6 changes L449F and P453L, Antivir. Ther., 6, 48.
Murphy, R. L., Gulick, R. M., DeGruttola, V., D’Aquila, R. T., Eron, J. J., Sommadossi, J. P., Currier, J. S., Smeaton, L., Frank, I., Caliendo, A. M., Gerber, J. G., Tung, R., and Kuritzkes, D. R. (1999) Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team, J. Infect. Dis., 179, 808–816.
Prado, J. G., Wrin, T., Beauchaine, J., Ruiz, L., Petropoulos, C., Clotet, B., D’Aquila, R., and Martinez-Picado, J. (2001) Lopinavir resistance of amprenavir-selected, replication-impaired mutants of HIV-1, Antivir. Ther., 6, 51.
Schmidt, B., Korn, K., Moschik, B., Paatz, B., Uberla, K., and Walter, H. (2000) Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors, Antimicrob. Agents Chemother., 44, 3213–3216.
Snowden, W., Shortino, D., Klein, A., Harris, W., Manohitharajah, V., Elston, R., Tisdale, M., and Maguire, M. (2000) Development of amprenavir resistance in NRTI-experienced patients: alternative mechanisms and correlation with baseline resistance to concomitant NRTIs, Antivir. Ther., 5(Suppl. 3), 84 [abstract 108].
Ziermann, R., Limoli, K., Das, K., Arnold, E., Petropoulos, C. J., and Parkin, N. T. (2000) A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir, J. Virol., 74, 4414–4419.
Goodgame, J., Hanson. C., Vafidis, I., et al. (1999) Amprenavir (141W94, APV)/3TC/ZDV exerts durable antiviral activity in HIV-1 infected antiretroviral therapy-naïve subjects through 48 weeks of therapy, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26–29 [abstract 509].
Cooper, D., Perrin, L., Kinloch, S., et al. (2000) Intervention with quadruple HAART [Combivir (COM)/abacavir (ABC)/amprenavir (APV)] intervention during primary HIV-1 infection (PHI) is associated with rapid viraemia clearance and decrease of immune activation, 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30–February 2 [abstract/poster 552].
Vernazza, P., Perrin, L., Vora, S., et al. (2000) Increased seminal shedding of HIV during primary infection augments the need for earlier diagnosis and intervention, 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30–February 2 [abstract/poster 564].
Eron, J., Junod, P., Becker, S., et al. (2000) NZT4002: 64 week analysis of combivir (COM)-based triple and quadruple therapy in antiretroviral-naive, HIV-1 infected subjects, 13th International AIDS Conference, Durban, South Africa, July 9–14 [abstract no. WeOrB608].
Murphy, R. L., Gulick, R. M., De Gruttola, V., et al. (1999) Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection, J. Infect. Dis., 179, 808–816.
Haubrich, R., Thompson, M., Schooley, R., et al. (1999) A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience, AIDS, 13(17), 2411–2420.
Eron, J. J., Jr., Smeaton, L. M., Fiscus, S. A., et al. (2000) The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS Clinical Trials Group Protocol 850), J. Infect. Dis., 181, 1622–1628.
Church, J, Rathore M, Rubio T., et al. (2000) A phase III study of amprenavir (APV, AgeneraseTM) in protease-inhibitor naïve and experienced HIV-infected children and adolescents, 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30–February 2 [abstract/poster 693].
Rodriguez-French, A., Boghossian, J., Gray, G. E., et al. (2004) The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients, J. Acquir. Immune Defic. Syndr., 35(1), 22–32.
Gathe, J. C., Jr., Ive, P., Wood, R., et al. (2004) SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients, AIDS, 18(11), 1529–1537.
Vertex (2003) Press release: Vertex reports preliminary 48-week data from Phase III study of 433908, an investigational HIV protease inhibitor (http://www.vpharm.com/Pressreleases2003/pr072403.html).
DeJesus, E., LaMarca, A., Sension, M., Beltran, C., and Yeni, P. (2003) The Context Study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results), 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10–14 [abstract 178].
Corbett, A. H., Davidson, L., Park, J. J., et al. (2004) Dose separation strategies to overcome the pharmacokinetic interaction of a triple protease inhibitor regimen containing fosamprenavir, lopinavir, and ritonavir, 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feburary 8–11 [abstract 611].
Kashuba, A. D., Tierney, C., Downey, G. F., et al. (2005) Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143, AIDS, 19(2), 145–152.
Walmsley, S., Leith, J., Katlama, C., et al. (2004) Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone and in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI1182.51, XVth International AIDS Conference, Bangkok, Thailand, July 11–16 [abstract WeOrB1236].
Wire, M. B., Ballow, C., Preston, S. L., et al. (2004) Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers, AIDS, 18(6), 897–907.
Eron, J., Jr., Yeni, P., Gathe, J., Jr., et al. (2006) KLEAN study team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomized non-inferiority trial, Lancet, 368(9534), 476–482
Elston, R. C., Yates, P., Tisdale, M., et al. (2004) GW433908 (908)/ritonavir (r): 48 week results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype, XVth International AIDS Conference, Bangkok, Thailand, July 11–16 [abstract MoOrB1055].
MacManus, S., Yates, P. J., Elston, R. C., et al. (2004) GW433908/ritonavir once daily in antiretroviral therapy-naïve HIV-infected patients: absence of protease resistance at 48 weeks, AIDS, 518(4), 651–655.
Fuster, D. and Clotet, B. (2005) Review of atazanavir: a novel HIV protease inhibitor, Expert Opin. Pharmacother., 6(9), 1565–1572.
Whiterel, G. (2001) BMS-232632 (Novartis/Bristol-Meyers Squibb), Curr. Opin. Investig. Drugs, 2, 340–347.
Gong, Y. F., Robinson, B. S., Rose, R. E., et al. (2000) In vitro resistance profile of the human immunodeficiency virus type-1 protease inhibitor BMS-232632, Antimicrob. Agents Chemother., 44, 2319–2326.
Colonno, R. J., Thiry, A., Limoli, K., and Parkin, N. (2003) Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors, Antimicrob. Agents Chemother., 47, 1324–1333.
Colonno, R., Rose, R., McLaren, C., Thiry, A., Parkin, N., and Friborg, J. (2004) Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naïve HIV-1-infected patients receiving ATV-containing regimens, J. Infect. Dis., 189, 1802–1810.
Schnell, T., Schmidt, B., Moschik, G., et al. (2003) Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples, AIDS, 17, 1258–1261.
Tackett, D., Child, M., Agarwall, S., et al. (2003) Atazanavir: a summary of two pharmacokinetics drug interaction studies in healthy subjects, 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10–14 [abstract 543].
Guffanty, M., De Pascalis, C. R., Seminari, E., et al. (2003) Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pretreated HIV-positive patients, AIDS, 17, 2669–2671.
Taburet, A. M., Piketty, C., Chazallon, C., et al. (2004) Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients, Anti\-microb. Agents Chemother., 48, 2031–2096.
Bristol-Myers Squibb Company. (2003) Reyataz™ (atazanavir) full prescribing information, Bristol-Myers Squibb Company, Princeton, NJ.
Sanne, I., Piliero, P., Squires, K., Thiry, A., and Schnittman, S. (2003) Results of a Phase II clinical trial at 48 weeks (AI424–007): a dose ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects, J. Acquir. Immune Defic. Syndr., 32, 18–29.
Murphy, R. L., Sanne, I., Canh, P., et al. (2003) Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results, AIDS, 17, 2603–2614.
Squires, K., Lazzarin, A., and Gatell, J. M. (2004) Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV, J. Acquir. Immune Defic. Syndr., 36, 1011–1019.
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults, N. Engl. J. Med., 341, 1865–1873.
Haas, D. W., Zala, C., Schrader, S., et al. (2003) Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial, AIDS, 17, 1339–1349.
Nieto-Cisneros, L., Zala, C., Fessel, W. J., et al. (2003) BMS AI424–043: antiviral efficacy, metabolic changes and safety of ATV versus LPV/RTV in combination with 2 NRTIs in patients who have experienced virology failure with prior PI-containing regimens: 24 wk results, 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, July 13–16 [abstract 117].
Johnson, M., De Jesus, E., Grinsztejn, B., et al. (2004) Long-term efficacy and durability of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in HIV–-infected patients with multiple virologic failures: 96-week results from a randomized, open-label trial BMS AI424-045, 7th International Congress on Drug Therapy in HIV Infection, Glagow, UK, November 14–18 [abstract PL 14.4].
Wood, R., Phanuphak, P., Cahn, P., et al. (2004) Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir, J. Acquir. Immune Defic. Syndr., 36, 684–692.
Agarwala, S., Eley, T., Villegas, C., et al. (2005) Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects, 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec City, Canada, April 28–30 [abstract 11].
Jemsek, J. G., Arathoon, E., Arlotti, M., et al. (2003) Atazanavir and efavirenz, each combined with fixed-dose zidovudine and lamivudine, have similar effects on body fat distribution in antiretroviral-naïve patients: 48-weeks results from the metabolic substudy of BMS AI423-034, Antivir. Ther., 8, L13.
Wang, S., Mulvey, R., Elosua, C., Flint, O. P., and Parker, P. A. (2003) Association of HIV-protease inhibitors with insulin resistance is related to potency of inhibition of GLUT4 and GLUT1 activity in adipocytes and miocytes, Antivir. Ther., 8, L36.
Carr, A., Miller, J., Law, M., and Cooper, D. A. (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome, AIDS, 14, F25–F32.
Haerter, G., Manfras, B. J., Mueller, M., Kern, P., and Trein, A. (2004) Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir, AIDS, 18, 952–955.
Zucker, S. D., Qin, X., Rouster, S. D., Yu, F., Green, R. M., Keshavan, P., Feinberg, J., and Sherman, K. E. (2001) Mechanism of indinavir-induced hyperbilirubinemia, Proc. Natl. Acad. Sci. U.S.A., 98(22), 12671–12676.
Sulkowski, M. S. (2004) Drug-induced liver injury associated with antiretroviral therapy that include HIV-1 protease inhibitors, Clin. Infect. Dis., 38(Suppl. 2), S90–S97.
Chang, H. R. and Pella, P. M. (2006) Atazanavir urolithiasis, N. Engl. J. Med., 355, 2158–2159.
Pacanowski, J., Poirier, J. M., Petit, I., Meynard, J. L., and Girard, P. M. (2006) Atazanavir urinary stones in an HIV-infected patient, AIDS, 20, 2131.
Anderson, P. L., Lichtenstein, K. A., Gerig, N. E., Kiser, J. J., and Bushman, L. R. (2007) Atazanavir-containing renal calculi in an HIV-infected patient, AIDS, 21, 1060–1062.
Izzedine, H., M’rad, M. B., Bardier, A., Daudon, M., and Salmon, D. (2007) Atazanavir crystal nephropathy, AIDS, 21(17), 2357–2358.
Sham, H. L., Kempf, D. J., Molla, A., et al. (1998) ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease, Antimicrob. Agents Chemother., 42(12), 3218–3224.
Cvetkovic, R. S. and Goa, K. L. (2003) Lopinavir/ritonavir: a review of its use in the management of HIV infection, Drugs, 63(8), 769–802.
Oldfield, V. and Plosker, G. L. (2006) Lopenavir/ritronavir: a review of its use in the management of HIV infection, Drugs, 66(9), 1275–1299.
Abbott Laboratories Ltd. Kaletra® (lopinavir/ritonavir) soft capsules: summary of product characteristics [online] (http://emc.medicines.org).
Abbott Laboratories. Kaletra® (lopinavir/ritonavir) tablets and oral solution. Prescribing information [online] (http://www.kaletra.com).
Abbott Laboratories. Kaletra® (lopinavir/ritonavir) capsules and oral solution. Product label information [online] (http://www.kaletra.com).
Eron, J., Feinberg, J., Kessler, H. A., et al. (2004) Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial, J. Infect. Dis., 189(2), 265–272.
Bertz, R., Foit, C., Ye, X., et al. (2002) Pharmacokinetics of once-daily vs. twice-daily Kaletra® (lopinavir/ritonavir) in HIV+ subjects, 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24–28 [abstract 126].
Johnson, A., Gathe, J. C., Jr., Podzamczer, D., et al. (2006) A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen, J. Acquir. Immune Defic. Syndr., 43(2), 153–160.
Murphy, R. L., Brun, S., Hicks, C., et al. (2001) ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results, AIDS, 15(1), F1–F9.
Molina, J. M., Wilkins, A., Domingo, P., et al. (2005) Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 96-week results, 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, July 24–27 [abstract WePe12.3C12 plus poster].
King, M. S., Bernstein, B. M., Walmsley, S. L., et al. (2004) Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients, J. Infect. Dis., 190(2), 280–284.
Murphy, R., Da Silva, B., McMillan, F., et al. (2005) Seven year follow-up of a lopinavir/ritonavir-based regimen in antiretroviral-naive subjects, 10th European AIDS Conference, Dublin, Ireland, November 17–20 [abstract PE7.9/3 plus poster].
Hicks, C., da Silva, B., Benson, C., et al. (2004) Extensive resistance testing during 5 years of lopinavir/ritonavir treatment in antiretroviral-naive HIV infected patients: results from study m97-720, 15th International AIDS Conference, Bangkok, Thailand, July 11–16 [abstract WeOrB1291 plus oral presentation].
Kempf, D. J., King, M. S., Bernstein, B., et al. (2004) Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine, J. Infect. Dis., 189(1), 51–60.
King, M., Lipman, B., Molla, A., et al. (2005) Assessing the potential for protease inhibitor cross-resistance in antiretroviral-naive patients experiencing viral rebound on a lopinavir/ritonavir-based regimen, 3rd European HIV Drug Resistance Workshop, Athens, Greece, March 30–April 1 [abstract 9.9 plus poster].
Molina, J. M., Gathe, J., Lim, P. L., et al. (2004) Comprehensive resistance testing in antiretroviral naive patients treated with once-daily lopinavir/ritonavir plus tenofovir and emtricitabine: 48-week results from study 418, 15th International AIDS Conference, Bangkok, Thailand, July 11–16 [abstract no. WePeB5701 plus poster].
Saez-Llorens, X., Violari, A., Deetz, C. O., et al. (2003) Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children, Pediatr. Infect. Dis. J., 22, 216–223.
Kempf, D. J., Isaacson, J. D., King, M. S., et al. (2001) Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients, J. Virol., 75(16), 7462–7469.
Mo, H., King, M. S., King, K., et al. (2005) Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates, J. Virol., 79(6), 3329–3338.
Delaugerre, C., Teglas, J. P., Treluyer, J. M., et al. (2004) Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir, J. Acquir. Immune Defic. Syndr., 37(2), 1269–1275.
Kempf, D. J., Isaacson, J. D., King, M. S., et al. (2002) Analysis of the virologic response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir, Antivir. Ther., 7(3), 165–174.
de Mendoza, C., Martin-Carbonero, L., Barreiro, P., et al. (2002) Salvage treatment with lopinavir/ritonavir (Kaletra), HIV Clin. Trials, 3(4), 304–309.
Yusa, K. and Harada, S. (2004) Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro, Curr. Pharm. Design, 10, 4055–4064.
Parkin, N. T., Chappey, C., and Petropoulos, C. J. (2003) Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance, AIDS, 17, 955–961.
Loutfy, M. R., Raboud, J. M., Walmsley, S. L., et al. (2004) Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens, Antivir. Ther., 4, 595–602.
Ribera, E., Azuaje, C., Lopez, R. M., et al. (2006) Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen, AIDS, 20(8), 1131–1139.
Rosso, R., Di Biagio, A., Dentone, C., et al. (2006) Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration, J. Anti\-microb. Chemother., 57(6), 1168–1171.
Connick, E., Lederman, M. M., Kotzin, B. L., Spritzler, J., Kuritzkes, D. R., St. Clair, M., Sevin, A. D., Fox, L., Chiozzi, M. H., Leonard, J. M., Rousseau, F., D’Arc Roe, J., Martinez, A., Kessler, H., and Landay, A. (2000) Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response, J. Infect. Dis., 181, 358–863.
Thaisrivongs, S. and Strohbach, J. W., (1999) Structure-based discovery of tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor, Biopolymers, 51(1), 51–58.
Turner, S. R., Strohbach, J. W., Tommasi, R. A., Aristoff, P. A., et al. (1998) Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro- 4-hydroxy-2-pyrone sulfonamide class, J. Med. Chem., 41(18), 3467–3476.
King, J. R. and Acosta, E. (2006) Tipranavir: a novel nonpeptidic protease inhibitor of HIV, Clin. Pharmacokinet., 45(7), 665–682.
Chong, K. T. and Pagano, P. J. (1997) In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates, Antimicrob. Agents Chemother., 41, 2367–2373.
Doyon, L., Tremblay, S., Wardrop, E., et al. (2003) Characterization of HIV-1 isolates showing decreased susceptibility to tipranavir and their inhibition by tipranavir containing drug mixtures, 12th International HIV Drug Resistance Workshop, Cabo San Lucas, Mexico, June 10–14 [abstract].
Schwartz, R., Kazanjian, P., Slater, L., et al. (2002) Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/RTV) in multiple PI-failure patients (BI 1182.2), 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24–28 [poster 562 T].
Moyle, G. J. and Gazzard, B. G. (1999) A risk-benefit assessment of HIV protease inhibitors, Drug Safety, 20, 299–321.
Jayaweera, D., Slater, L., Haas, D., et al. (2002) Susceptibility profile of tipranavir at baseline and subsequent virologic response in a cohort of patients with single-protease inhibitor failure, 2nd International HIV Workshop on Management of Treatment-Experienced Patients, San Diego, CA, September 26–27 [poster P5].
McCallister, S., Neubacher, D., Verblest, W., et al. (2002) Resistance profile of tipranavir (TPV) in patients with single- or multiple-protease inhibitor (PI) failure, HIV DART 2002: Frontiers in Drug Development for Antiretroviral Therapies, Naples, FL, December 15–19 [abstract].
Hall, D., McCallister, S., Neubacher, D., et al. (2003) Characterization of treatment-emergent resistance mutations in two phase II studies of tipranavir (TPV), 12th International HIV Drug Resistance Workshop, Cabo San Lucas, Mexico, June 10–14 [poster 13].
Gathe, J., Kohlbrenner, V. M., Pierone, G., et al. (2003) Tipranavir/ritonavir (TPV/r) demonstrates potent efficacy in multiple protease inhibitor (PI)-experienced patients: BI 1182.52, 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10–14 [presentation 179].
McCallister, S., Kohlbrenner, V., Villacian, J., et al. (2004) 24-week combined analysis of the TPV RESIST studies of 1483 treatment-experienced patients given either tipranavir/ritonavir (TPV/r) or an optimized standard of care regimen using 1 of 4 RTV-boosted comparator PIs (CPI/r), HIV DART 2004: Frontiers in Drug Development for Antiretroviral Therapies, Montego Bay, Jamaica, December 12–16 [abstract 060].
McCallister, S., Sabo, J. P., Mayers, D. L., et al. (2002) An open-label, steady-state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal, healthy volunteers (BI 1182.5), 9th Conference on Retroviruses and Opportunistic Infections, Seatlle, WA, February 24–28 [poster 434 W].
Kilgore, N., Reddick, M., Zuiderhof, M., et al. (2007) Characterization of PA1050040, a second generation HIV-1 maturation inhibitor, 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22–25 [abstract MOPDX05].
Phillips, L., Borin, M. T., Hopkins, N. K., et al. (2000) The pharmacokinetics of nucleoside reverse transcriptase inhibitors when coadministered with the HIV protease inhibitor tipranavir in HIV-1 infected patients, 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30–February 4 [poster 81].
Fletcher, C. V., Kawle, S. P., Kakuda, T. N., et al. (2000) Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons, AIDS, 14, 2137–2144.
GlaxoSmithKline (2003) Retrovir (zidovudine) [package insert]. GlaxoSmithKline, Research Triangle Park, NC.
GlaxoSmithKline (2004) Ziagen (abacavir) [package insert]. GlaxoSmithKline, Research Triangle Park, NC.
Bristol-Myers Squibb (2005) Sustiva (efavirenz) [package insert]. Bristol-Myers Squibb, Princeton, NJ.
Boehringer Ingelheim (2005) Viramune (nevirapine) [package insert]. Boehringer Ingelheim, Ridgefield, CT.
Kashuba, A. D., Tierney, C., Downey, G. F., et al. (2005) Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results, AIDS, 19, 145–152.
Roszko, P. J., Curry, K., Brazina, B., et al. (2003) Standard doses of efavirenz (EFV), zidovudine (ZDV), tenofovir (TDF), and didanosine (ddI) may be given with tipranavir/ritonavir (TPV/r), 2nd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment, Paris, France, July 13–16 [poster 865].
Boehringer Ingelheim (2005) Aptivus (tipranavir) [package insert]. Boehringer Ingelheim, Ridgefield, CT.
Sabo, J., MacGregor, T., Lamson, M., et al. (2001) Pharmacokinetics of tipranavir and nevirapine, 10th Annual Canadian Conference on HIV/AIDS Research, Toronto, Canada, May 31–June 3 [poster 249P].
Goebel, F. D., Sabo, J. P., MacGregor, T. R., et al. (2202) Pharmacokinetic drug interaction screen of three doses of tipranavir/ritonavir (TPV/r) in HIV-infected patients on stable highly active antiretroviral therapy (HAART), HIV DART 2002: Frontiers in Drug Development for Antiretroviral Therapies, Naples, FL, December 15–19 [abstract].
Curry, K., Samuels, C., Leith, J., et al. (2004) Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI 1182.51, 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, Italy, April 1–3 [poster 5.1].
Hicks, C. (2004) RESIST-1: A phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., October 30–November 2 [abstract H-1137a].
Hicks, C. B., Cahn, P., Cooper, D. A., Walmsley, S. L., Katlama, C., Clotet, B., Lazzarin, A., Johnson, M. A., Neubacher, D., Mayers, D., Valdez, H., and on behalf of the RESIST Investigator Group (2006) Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug resistant patients with tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials, Lancet, 368(9534), 466–475.
Cahn, P. (2004) 24-Week data from RESIST 2: phase 3 of the efficacy and safety of either tipranavir/ritonavir (TRV/r) or an {optimized} ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV+ patients, 7th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 14–18 [abstract PL 14.3].
Katlama, C., Walmsley, S., Hicks, C., Cahn, P., Neubacher, D., and Villacian, J., for the RESIST Investigator Group (2006) Tipranavir achieves twice the rate of treatment response and prolongs {durability} of response vs comparator PI in ART-experienced patients, independent of baseline CD4 cell count or viral load: week 48 RESIST 1 and 2 combined analyses, 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5–8.
Farthing, C., Ward, D., Hicks, C., Johnson, M., Cauda, R., and Cahn, P. (2007) 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27–30, [abstract. H-1385].
Gazzard, B., Antinori, A., and Cheli, C. (2006) Combined analysis of RESIST 96 week data: durability and efficacy of tipranavir/r in treatment experienced patients, 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 12–16 [abstract P23].
Madruga, J. V., Berger, D., McMurchie, M., and the TITAN Study Group (2007) Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial, Lancet, 370(9581), 49–58.
Surleraux, D. L., Tahri, A., Verschueren, W. G., Pille, G. M., de Kock, H. A., et al. (2005) Discovery and selection of TMC114, a next generation HIV-1 protease inhibitors, J. Med. Chem., 48(6), 1813–1822.
Kovalevsky, A. Y., Tie, Y., Liu, F., Boross, P. I., Wang, Y. F., et al. (2006) Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M, J. Med. Chem., 49(4), 1379–1387.
Tibotec Therapeutics (2006) Darunavir [package insert], Tibotec Therapeutics, East Bridgewater, NJ.
De Meyer, S., Hill, A., De Baere, I., et al. (2006) Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: preliminary analysis of data from PI-experienced patients from POWER 1 and POWER 2, 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5–9 [abstract 157].
De Meyer, S., Vangeneugden, T., Lefebvre, E., van Marck, H., Azijn, H., De Baere, I., van Baelen, B., and de Béthune, M. P. (2006) Response to TMC114 is based on genotypic/phenotypic resistance: POWER 1/2/3 pooled analysis, 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 12–16 [poster 196].
Sekar, V. J., De Pauw, M., Mariën, K., et al. (2007) Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers, Antivir. Ther., 12(4), 509–514.
Arasteh, K., Clumeck, N., Pozniak, A., Lazzarin, A., De Meyer, S., Muller, H., Peeters, M., Rinehart, A., and Lefebvre, E. (2005) TMC114-C207 Study Team: TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial, AIDS, 19(9), 943–947.
De Meyer, S., Azijn, H., Surleraux, D., Jochmans, D., Tahri, A., Pauwels, R., Wigerinck, P., and de Bethune, M. P. (2005) TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates, Antimicrob. Agents Chemother., 49(6), 2314–2321.
Molina, J. M., Cohen, C., Katlama, C., Grinsztejn, B., Timerman, A., Pedro, R., De Meyer, S., de Béthune, M. -P., Vangeneugden, T., and Lefebvre, E. (2006) TMC114/r in treatment-experienced HIV patients in POWER 3: 24-week efficacy and safety analysis, XVIth International AIDS Conference, Toronto, Canada, August 13–18 [poster TUPE 0060].
Cremieux, A. C., Gillotin, C., Demarles, D., Yuen, G. J., Raffi, F., and the AZ110002 Study Group (2001) A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults, Pharmacotherapy, 21, 424–430
Shapiro, M., Ward, K. M., and Stern, J. J. (2001) A near-fatal hypersensitivity reaction to abacavir: case report and literature review, AIDS Read, 11(4), 222–226.
Frissen, P. H., De Vries, J., Weigel, H. M., and Brinkman, K. (2001) Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity, AIDS, 15(2), 289.
Escaut, L., Liotier, J. Y., Albengres, E., Cheminot, N., and Vittecoq, D. (1999) Abacavir rechallenge has to be avoided in case of hypersensitivity reaction, AIDS, 13(11), 1419–1420.
Staszewski, S., Keiser, P., Montaner, J., et al. (2001) Abacavir-lamivudine-zidovudine versus indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial, J. AM. Med. Assoc., 285(9), 1155–1163.
Kakuda, T. N. (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity, Clin. Ther., 22(6), 685–708.
Jonhson, A. A., Ray, A. S., Hanes, J., et al. (2001) Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase, J. Biol. Chem., 276(44), 40847–40857.
Tikhomirov, V., Namek, K., and Hindes, R. (1999) Agranulocytosis induced by abacavir, AIDS, 13(11), 1420–1421.
Lanier, E. R., Ait-Khaled, M., Scott, J., et al. (2004) Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors, Antivir. Ther., 9(1), 37–45.
Latham, V., Stebbing, J., Mandalia, S., et al. (2005) Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol, J. Antimicrob. Chemother., 56(1), 186–189.
Sosa, N., Hill-Zabala, C., DeJesus, E., et al. (2005) Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL), J. Acquir. Immune Defic. Syndr., 40(4), 422–427.
Fallon, J., Ait-Khaled, M., Thomas, D. A., et al. (2002) HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients, AIDS, 16(3), 387–396.
Paterson, D. L., Swindells, S., Mohr, J., et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection, Ann. Intern. Med., 133, 21–30.
Moyle, G., Fisher, M., Reilly, G., et al. (2007) A randomized comparison of continued zidovudine plus lamivudine BID (Combivir, CBV) versus switching to tenofovir DF plus emtricitabine (Truvada, TVD), each plus efavirenz (EFV), in stable HIV-infected persons: results of a planned 24-week analysis, 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22–25 [abstract WEPEB028].
Gallant, J. E., DeJesus, E., Arribas, J. R., et al., for Study 934 Group (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV, N. Engl. J. Med., 354, 251–260.
Arribas, J., Pozniak, A., Gallant, J., et al. (2007) Three-year safety and efficacy of emtricitabine (FT)/tenofovir DF (TDF) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) in antiretroviral treatment-naïve patients, 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, July 22–25 [abstract WEPEB029].
Staszewski, S., Keiser, P., Gathe, J., Haas, D., Montaner, J., et al. (1999) Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapy-naive adults at 48 weeks (CN3005), 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26–29 [abstract no. 505].
Rodriguez-French, A., Boghossian, J., Gray, G. E., et al. (2004) The NEAT Study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients, J. Acquir. Immune Defic. Syndr., 35, 22–32.
Gathe, J., Ive, P., Wood, R., et al. (2004) SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1-infected patients, AIDS, 18, 1529–1537.
Gazzard, B., DeJesus, E., Cahn, P., et al. (2003) Abacavir (ABC) once daily (OAD) plus lamivudine (3TC) OAD in combination with efavirenz (EFV) OAD is well-tolerated and effective in the treatment of antiretroviral therapy (ART) naïve adults with HIV-1 infection (Zodiac Study: CNA30021), 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14–17 [abstract H1722b].
DeJesus, E., Herrera, G., Teofilo, E., et al., for the CNA30024 Study Team (2004) Abacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviral-naïve HIV-infected adults, Clin. Infect. Dis., 39, 38–46.
Sosa, N., Hill-Zabala, C., DeJesus, E., Herrera, G., Florance, A., Watson, M., Vavro, C., and Shaefer, M. (2005) Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks, J. Acquir. Immune Defic. Syndr., 40(4), 422–427.
Kubota, M., Cohen, C., Scribner, A., et al. (2006) Short-term safety and tolerability of ABC/3TC administered once-daily (QD) compared with the separate components administered twice-daily (BID): results from ESS101822 (ALOHA), 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 27–30 [poster H-1904].
Martinez, E., Arranz, J. A., Podzamczer, D., et al. (2007) Efficacy and safety of NRTIs switch to tenofovir plus emtricitabine (Truvada) vs. abacavir plus lamivudine (Kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: the BICOMBO study, 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22–25 [abstract WESS102].
Mallal, S., Phillips, E., Carosi, G., et al. (2007) PREDICT-1: a novel randomised prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in HIV-1 infected subjects (study CNA106030), 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia, July 22–25 [abstract WESS101].
Trottier, B., Thomas, R., Nguyen, V. K., et al. (2007) How effectively HLA screening can reduce the early discontinuation of abacavir in real life? 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment, and Prevention, Sydney, Australia, July 22–25 [abstract MOAB103].
Saag, M., Balu, R., Brachman, P., et al. (2007) High sensitivity of HLA-B*5701 in whites and blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR), 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment, and Prevention, Sydney, Australia, July 22–25 [abstract WEAB305].
Goicoechea, M. and Best, B. (2007) Efavirenz/emtricitabine/ tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin. Pharmacother., 8(3), 371–382.
Pozniak, A. L., Gallant, J. E., DeJesus, E., et al. (2006) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes–-a 96-week analysis, J. Acquir. Immune Defic. Syndr., 4, 535–540.
Gallant, J. E., Staszewski, S., Pozniak, A. L. et al. (2004) Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial, J. Am. Med. Assoc., 292, 191–201.
Berger, E. A. (1997) HIV entry and tropism: when one receptor is not enough, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22–26, [abstract S7].
Fox, J. and Pease, J. E. (2005) The molecular and cellular biology of CC chemokines and their receptors, Curr. Topics Membr., 55, 73–102.
Blanpain, C., Libert, F., Vassart, G., and Parmentier M. (2002) CCR5 and HIV infection, Receptor Channels, 8(1), 19–31.
Galvani, A. and Slatkin, M. (2003) Evaluating plague and smallpox as historical selective pressures for the CCR5-Δ32 HIV-resistance allele, Proc. Natl. Acad. Sci. U.S.A., 100(25), 15276–15279.
Stephens, J., Reich, D. E., Goldstein, D. B., et al. (1998) Dating the origin of the CCR5-delta32 AIDS-resistance allele by the coalescence of haplotypes, Am. J. Hum. Genet., 62(6), 1507–1515.
Hedrick, P. W. and Verrelli, B. C. (2006) “Ground truth” for selection on CCR5-Δ32, Trends in Genet., 22(6), 293–296.
Glass, W. G., McDermott, D. H., and Lim, J. K. (2006) CCR5 deficiency increases risk of symptomatic West Nile virus infection, J. Exp. Med., 203(1), 35–40.
Duncan, S. R., Scott, S., and Duncan, C. J. (2005) Reappraisal of the historical selective pressures for the CCR5-Δ32 mutation, J. Med. Genet., 42, 205–208.
Sabeti, P. C., Walsh, E., Schaffner, S. F., et al. (2005), The case for selection at CCR5-Delta32, PLoS Biology, 3(11), e378.
Welch, B. D., VanDemark, A. P., Heroux, A., Hill, C. P, and Kay, M. S. (2007) Potent D-peptide inhibitors of HIV-1 entry, Proc. Natl. Acad. Sci. U.S.A., 104(43), 16828–16833.
Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoprotein, Cell, 89, 263–273.
Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997) Atomic structure of the ectodomain from HIV-1 gp41, Nature, 387, 426–430.
Tan, K., Liu, J., Wang, J., Shen, S., and Lu, M. (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41, Proc. Natl. Acad. Sci. U.S.A., 94, 12303–12308.
Eckert, D. M. and Kim, P. S. (2001) Mechanisms of viral membrane fusion and its inhibition, Annu. Rev. Biochem., 70, 777–810.
Chan, D. C. and Kim, P. S. (1998) HIV Entry and its inhibition, Cell, 93, 681–684.
Furuta, R. A., Wild, C. T., Weng, Y., and Weiss, C. D. (1998) Capture of an early fusion-active conformation of HIV-1 gp41, Nat. Struct. Biol., 5, 276–279.
Root, M. J. and Steger, H. K. (2004) HIV-1 gp41 as a target for viral entry inhibition, Curr. Pharm. Des., 10, 1805–1825.
Eckert, D. M., Malashkevich, V. N., Hong, L, H., Carr, P, A., and Kim, P. S. (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket, Cell, 99, 103–115.
Root, M. J., Kay, M. S., and Kim, P. S. (2001) Protein design of an HIV-1 entry inhibitor, Science, 291, 884–888.
Chan, D. C., Chutkowski, C. T., and Kim, P. S. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target, Proc. Natl. Acad. Sci. U.S.A., 95, 15613–15617.
Louis, J. M., Bewley, C. A., and Clore, G. M. (2001) Design and properties of NCCG-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity, J. Biol. Chem., 276, 29485–29489.
Eckert, D. M. and Kim, P. S. (2001) Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region, Proc. Natl. Acad. Sci. U.S.A., 98, 11187–11192.
Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., and Matthews, T. J. (1994) Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection, Proc. Natl. Acad. Sci. U.S.A., 91, 9770–9774.
Rimsky, L. T., Shugars, D. C., and Matthews, T. J. (1998) Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides, J. Virol., 72, 986–993.
Cooper, D., on behalf of the Alliance Investigator Group (2005) An analysis of the correlation between the severity of injection site reactions and the amount of subcutaneous fat in the Alliance cohort, 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22–25 [poster 838].
Thompson, M., DeJesus, E., Richmond, G., et al. (2006) Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects, AIDS, 20(3), 397–404.
DeJesus, E., Zolopa, A., Farthing, C., et al. (2007) Response to darunavir/ritonavir (DRV/r) combined with enfuvirtide (ENF)-containing ARV in triple-class experienced patients was not predicted by baseline darunavir (DRV) sensitivity or viral tropism (VT): the BLQ study preliminary results, 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22–25 [poster WEPEB039].
Wiznia, A., Church, A., Emmanuel, P., and the T20-310 Study Group (2007) Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients, Pediatr. Infect. Dis. J., 26(9), 799–805.
Tschida, S., Zappa, A., and Godwin, M. (2006) An ongoing nonrandomized large prospective evaluation of alternative injection devices (Biojector B2000, standard needles/syringes, or insulin needles/syringes) for enfuvirtide in a national community-based specialty pharmacy, XVIth International AIDS Conference, Toronto, Canada, August 13–18 [poster TUPE0147].
Harris, M., Joy, R., Larsen, G.,Valyi, M., Walker, E., et al. (2006) Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector), AIDS, 20(5), 719–723.
Paterlini, M. G. (2002) Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity, Biophys. J., 83(6), 3012–3031.
Hoffman, T. L., LaBranche, C. C., Zhang, W., Canziani, G., Robinson, J., Chaiken, I., Hoxie, J. A., and Doms, R. W. (1999) Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein, Proc. Natl. Acad. Sci. U.S.A., 96, 6359–6364.
Kolchinsky, P., Mirzabekov, T., Farzan, M., Kiprilov, E., Cayabyab, M., Mooney, L. J., Choe, H., and Sodroski, J. (1999) Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication, J. Virol., 73, 8120–8126.
Rizzuto, C. D., Wyatt, R., Hernandez-Ramos, N., Sun, Y., Kwong, P. D., Hendrickson, W. A., and Sodroski, J. (1998) A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding, Science, 280, 1949–1953.
Wu, L., Gerard, N. P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., et al. (1996) CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5, Nature, 384, 179–183.
Berger, E. A., Doms, R. W., Fenyo, E. M., Korber, B. T., Littman, D. R., et al. (1998) A new classification for HIV-1, Nature, 391, 240.
Robertson, D. L., Anderson, J. P., Bradac, J. A., Carr, J. K., Foley, B., et al. (2000) HIV-1 nomenclature proposal, Science, 288, 55–56.
Lucas, A. D., Gaudieri, S., Rauch, A., et al. (2005) Cellular tropism of HIV-1 mediated and constrained by coreceptor dependencies, J. Vir. Entry, 1, 17–27.
Clotet, B. (2007) CCR5 Inhibitors: promising yet challenging, J. Infect. Dis., 196, 178–180.
Dragic, T., Trkola, A., Lin, S. W., Nagashima, K. A., Kajumo, F., Zhao, L., et al. (1998) Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry, J. Virol., 72, 279–285.
Samson, M., LaRosa, G., Libert, F., Paindavoine, P., Detheux, M., Vassart, G., and Parmentier, M. (1997) The second extracellular loop of CCR5 is the major determinant of ligand specificity, J. Biol. Chem., 272, 24934–24941.
Blanpain, C., Doranz, B. J., Vakili, J., Rucker, J., Govaerts, C., Baik, S. S., et al. (1999) Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein, J. Biol. Chem., 274, 34719–34727.
Dragic, T., Trkola, A., Thompson, D. A., Cormier, E. G., Kajumo, F. A., et al. (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5, Proc. Natl. Acad. Sci. U.S.A., 97, 5639–5644.
Mayer, H., van der Ryst, E., Saag, M., et al. (2006) Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a Phase 2b exploratory trial, XVI International AIDS Conference, Toronto, Canada, August 13–18 [abstract THLB0215].
Lalezari, J., Goodrich, J., DeJesus, E., Lampiris, H., Gulick, R., et al. on behalf of the MOTIVATE 1 Study Group. (2007) Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of Phase 2b/3 studies, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25–28 [presentation 104bLB].
Nelson, M., Fätkenheuer, G., Konourina, I., Lazzarin, A., Clumeck, N., Horban, A., et al., on behalf of the MOTIVATE 2 Study Group (2007) Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of Phase 2b/3 studies, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25–28 [presentation 104aLB].
Fätkenheuer, G., Pozniak, A. L., Johnson, M. A., et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1, Nat. Med. 11, 1170–1172.
McHale, M., Abel, S., Russell, D., et al. (2005) Overview of Phase I and 2a safety and efficacy data of maraviroc (UK-427,857), 3rd International AIDS Society (IAS) Conference on the HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, July 24–27 [abstract TuOa0204].
Tsibris, A. M. and Kuritzkes, D. R. (2007) Chemokine antagonists as therapeutics: focus on HIV-1, Annu. Rev. Med., 58, 445–459.
GlaxoSmithKline (2005) Statement to HIV patient community: information from GlaxoSmithKline on changes to studies of investigational CCR5 entry inhibitor aplaviroc (GW873140), GlaxoSmithKline, Research Triangle Park, NC.
Steel, H. M. (2005) Special presentation on aplaviroc-related hepatotoxicity, 10th European AIDS Conference, Dublin, Ireland, November 17–20 [abstract].
Temesdgen, Z., Warnke, D., and Kasten, M. J. (2006) Current status of antiretroviral therapy, Expert Opin. Chemother., 7(12), 1541–1554.
Saag, M., Ive, P., Heers, J., et al. (2007) A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study, 4th International AIDS Society (IAS) Conference on HIV Pathogeneis, Treatment and Prevention, Sydney, Australia, July 22–25 [abstract WESS104].
Reeves, J. D., Han, D., Liu, Y., et al. (2007) Enhancements to the Trofile HIV coreceptor tropism assay enable reliable detection of CXCR4-using subpopulations at less than 1%, 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20 [abstract H-1026].
Strizki, J. M., Tremblay, C., Xu, S., et al. (2005) Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1, Antimicrob. Agents Chemother., 49(12), 4911–4919.
Schurmann, D., Fätkenheuer, G., Reynes, J. (2007) Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults, AIDS, 21(10), 1293–1299.
Gulick, R., Su, Z., Flexner, C., Hughes, M. (2007) ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results, 4th International AIDS Conference (IAS) on Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22–25 [abstract 1623].
Gulick, R., Haas, D., Collier, A. C., Lennox, J., Parker, C., and Greaves, W. (2007) Two-year follow-up of treatment-experienced patients on vicriviroc (VCV), 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20 [abstract H-1030].
Fätkenheuer, G., Hoffmann, C., Sansone-Parsons, A., Greaves, W., and Dunkle, L. (2007) CD4 lymphocyte and leukocyte response to vicriviroc (VCV) in 282 HIV-infected treatment-naive and experienced subjects: pooled data from 4 randomized clinical trials, 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, October 25–27 [abstract H-1031].
Savarino, A. (2006) A historical sketch of the discovery and development of HIV-1 integrase inhibitors, Expert Opin. Investig. Drugs, 15(12), 1507–1522.
Pommier, Y., Johnson, A. A., and Marchand, C. (2005) Integrase inhibitors to treat HIV/AIDS, Nat. Rev. Drug Discov., 4(3), 236–248.
Goldgur, Y., Craigie, R., Cohen, R., et al. (1999) Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design, Proc. Natl. Acad. Sci. U.S.A., 96(23), 13040–13043.
Wang, J. Y., Ling, H., Yang, W., et al., (2001) Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein, EMBO J., 20(24), 7333–7343.
Chen, J. C. H., Krucinski, J., Miercke, W., et al. (2000) Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding, Proc. Natl. Acad. Sci. U.S.A., 97(15), 8233–8238.
Tsurutani, N., Kubo, M., Maeda, Y., et al. (2000) Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells, J. Virol., 74, 4795–4806.
Zhu, K., Dobard, C., and Chow, S. A. (2004) Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase, J. Virol., 78, 5045–5055.
Brown, P. O. (1998) Integration. In: Retroviruses (Coffin, J. M., Hughes, S. H., and Varmus, H. E., eds.), Cold Spring Harbor Press, Cold Spring Harbor, NY, pp. 161–203.
Turlure, F., Devroe, E., Silver, P. A., and Engelman, A. (2004) Human cell proteins and human immunodeficiency virus DNA integration, Front. Biosci., 9, 3187–3208.
Hindmarsh, P., Ridky, T., Reeves, R., Andrake, M., Skalka, A. M., and Leis, J. (1999) HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro, J. Virol., 73, 2994–3003.
Farnet, C. and Bushman, F. D. (1997) HIV-1 cDNA integration: requirement of HMG I (Y) protein for function of preintegration complexes in vitro, Cell, 88, 483–492.
Bukrinsky, M. I., Sharova, N., Dempsey, M. P., Stanwick, T. L., Bukrinskaya, A. G., Haggerty, S., and Stevenson, M. (1992) Active nuclear import of human immunodeficiency virus type 1 preintegration complexes, Proc. Natl. Acad. Sci. U.S.A., 89, 6580–6584.
Chow, S. A., Vincent, K. A., Ellison, V., and Brown, P. O. (1992) Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus, Science, 255, 723–726.
Yoder, K. E. and Bushman, F. D. (2000) Repair of gaps in retroviral DNA integration intermediates, J. Virol., 74, 11191–11200.
Daniel, R., Greger, J. G., Katz, R. A., Taganov, K., et al. (2004) Evidence that stable retroviral transduction and cell survival following DNA integration depend on components of the nonhomologous end joining repair pathway, J. Virol., 78, 8573–8581.
Myers, R. E. and Pillay, D. (2007) HIV-1 integrase sequence variation and covariation, Antivir. Ther., 12, S65.
Van Baelen, K., Clynhens, M., Rondelez, E., et al. (2007) Low level of baseline resistance to integrase inhibitors L731,988 and L870,810 in randomly selected subtype B and non-B HIV-1 strains, Antivir. Ther., 12, S7.
Ceccherini-Silberstein, F., Malet, I., Perno, C. F., et al. (2007) Specific mutations related to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients, Antivir. Ther., 12, S6.
Roquebert, B., Dmaond, F., Descamps, D., et al. (2007) Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors: raltegravir and elvitegravir, Antivir. Ther., 12, S92.
Hazuda, D. J., Miller, M. D., Hguyen, B. Y., et al. (2007) Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection, Antivir. Ther., 12(5), S10.
Malet, I., Delelis, O., Calvez, V., et al. (2007) Biochemical characterizations of the effect of mutations selected in HIV-1 integrase gene associated with failure to raltegravir (MK-0518), Antivir. Ther., 12(5), S9.
Cooper, D., Gatell, J., Rockstroh, J., et al. (2007) Results from BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25–28 [abstract 105aLB].
Steigbigel, R., Kumar, P., Eron, J., et al. (2007) Results from BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25–28 [abstract 105bLB].
Grinsztejn, B., Nguyen, B., Katlama, C., et al. (2007) 48 week efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus, 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 17–20 [abstract H-713].
Grinsztejn, B., Nguyen, B., Katlama, C., et al. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial, Lancet, 369(9569), 1261–1269.
Markowitz, M., Nguyen, B. Y., Gotuzzo, E., et al. (2007) Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients: results of a 48-week controlled study, J. Acquir. Immune Defic. Syndr., 46(2), 125–133.
Markowitz, M., Morales-Ramirez, J. O., Nguyen, B-Y., et al. (2006) Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals, J. Acquir. Immune Defic. Syndr., 43(5), 509–515.
Iwamoto, M., Wenning, L. A., Petry, A. S., et al. (2007) Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects, Clin. Pharmacol. Ther., 83(2), 293–299.
Cahn, P. and Sued, O. (2007) Raltegravir: a new antiretroviral class for salvage therapy, Lancet, 369, 1235–1236.
Grinsztejn, B., Nguyen, B., Katlama, C., et al. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial, Lancet, 369(9569), 1261–1269.
DeJesus, E., Berger, D., Markowitz, M., et al. (2006) The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naive and experienced patients, 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5–8 [abstract 159LB].
Zolopa, A. R., Mullen, M., Berger, D., et al. (2007) The HIV integrase inhibitor GS-9137 demonstrates potent ARV activity in treatment-experienced patients, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25–28, [oral presentation/abstract 143LB].
Zolopa, A. R., Lampiris, H., Blick, G., et al (2007) The HIV integrase inhibitor elvitegravir (EVG/r) has potent and durable activity in treatment-experienced patients with active optimized backgroung therapy (OBT), 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20 [oral presentation/abstract H-714].
Ledford, R., Margot, N., Miller, M., et al. (2007) Elvitegravir (GS-9137/JTK-303), an HIV-1 integrase inhibitor, has additive to synergistic interactions with other antiretroviral drugs in vitro, 4th International AIDS Society (IAS) Conference on Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22–25 [abstract/poster MOPEA052].
Jones, G., Ledford, R., Yu, F., et al. (2007) Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303), 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25–28 [poster 627].
Li, F., Goila-Gaur, R., Salzwedel, K., Kilgore, N. R., Reddick, M., et al. (2003) PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing, Proc. Natl. Acad. Sci. U.S.A., 100(23), 13555–13560.
Swanstrom, R. and Wills, J. W. (1997) Synthesis, assembly, and processing of viral proteins. In: Retroviruses (Weiss, R., Teich, N., Varmus, H., and Coffin, J. M., eds.), Cold Spring Harbor Laboratory Press, Plainview, NY, pp. 263–334.
Freed, E. O. (1998) HIV-1 gag proteins: diverse functions in the virus life cycle, Virology, 251, 1–15.
Gottlinger, H. G., Dorfman, T., Sodroski, J. G., and Haseltine, W. A. (1991) Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release, Proc. Natl. Acad. Sci. U.S.A., 88, 3195–3199.
Huang, M., Orenstein, J. M., Martin, M. A., and Freed, E. O. (1995) p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease, J. Virol., 69, 6810–6818.
Freed, E. O. (2002) Viral late domains, J. Virol., 76, 4679–4687.
Kräusslich, H. G., Schneider, H., Zybarth, G., Carter, C. A., and Wimmer, E. (1988) Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli, J. Virol., 62, 4393–4397.
Mervis, R. J., Ahmad, N., Lillehoj, E. P., Raum, M. G., Salazar, F. H., Chan, H. W., and Venkatesan, S. (1988) The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors, J. Virol., 62, 3993–4002.
Erickson-Viitanen, S., Manfredi, J., Viitanen, P., Tribe, D. E., Tritch, R., Hutchison, C. A., Loeb, D. D., and Swanstrom, R. (1989) Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease, AIDS Res. Hum. Retroviruses, 5, 577–591.
Kräusslich, H. G., Facke, M., Heuser, A. M., Konvalinka, J., and Zentgraf, H. (1995) The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity, J. Virol., 69, 3407–3419.
Wiegers, K., Rutter, G., Kottler, H., Tessmer, U., Hohenberg, H., and Kräusslich H. G. (1998) Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites, J. Virol., 72, 2846–2854.
Accola, M. A., Höglund, S., and Göttlinger, H. G. (1998) A putative α-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly, J. Virol., 72, 2072–2078.
Kaplan, A. H., Zack, J. A., Knigge, M., Paul, D. A., Kempf, D. J., Norbeck, D. W., and Swanstrom, R. (1993) Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles, J. Virol. 67, 4050–4055.
Demirov, D. G., Orenstein, J. M., and Freed, E. O. (2002) The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner, J. Virol., 76, 105–117.
Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., Wang, H. E., Wettstein, D. A., Stray, K. M., Cote, M., Rich, R. L., et al. (2001) Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding, Cell, 107, 55–65.
Demirov, D. G., Ono, A., Orenstein, J. M., and Freed, E. O. (2002) Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function, Proc. Natl. Acad. Sci. U.S.A., 99, 955–960.
Liang, C., Rong, L., Laughrea, M., Kleiman, L., and Wainberg, M. A. (1998) Compensatory point mutations in the human immunodeficiency virus type 1 Gag region that are distal from deletion mutations in the dimerization initiation site can restore viral replication, J. Virol., 72, 6629–6636.
Liang, C., Rong, L., Cherry, E., Kleiman, L., Laughrea, M., and Wainberg, M. A. (1999) Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins, J. Virol., 73, 6147–6151.
PR Newswire. (2004) Panacos Pharmaceuticals’ HIV Drug Candidate, PA-457, exhibits potent anti-HIV activity following a single dose in HIV-infected patients. Press release, November 23 (http://www.pressurebiosciences.com/news_releases/article-157.html).
Fujioka, T., Kashiwada, Y., Kilkuskie, R. E., Cosentino, L. M., Ballas, L. M., Jiang, J. B., Janzen, W. P., Chen, I. S., and Lee, K. H. (1994) Anti-AIDS agents. 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids, J. Nat. Prod., 57, 243–247.
Kashiwada, Y., Hashimoto, F., Cosentino, L. M., Chen, C. H., Garrett, P. E., and Lee, K. H. (1996) Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents, J. Med. Chem., 39, 1016–1017.
Kanamoto, T., Kashiwada, Y., Kanbara, K., Gotoh, K., Yoshimori, M., Goto, T., Sano, K., and Nakashima, H. (2001) Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation, Antimicrob. Agents Chemother., 45, 1225–1230.
Martin, D. E., Blum, R., Wilton, J., et al. (2007) Safety and pharmacokinetics of bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers, Antimicrob. Agents Chemother., 51(9), 3063–3066.
Beatty, G., Lalezari, J., Eron, J., et al. (2005) Safety and antiviral activity of PA-457, the first-in-class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients, 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., December 16–19 [abstract H-416d; abstract LB-27].
Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators, N. Engl. J. Med., 338, 853–860.
Hogg, R. S., Yip, B., Kully, C., et al. (1999) Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens, Can. Med. Assoc. J., 160, 695–665.
Moyle, G. and Carr, A. (2002) HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities, HIV Clin. Trials, 3, 89–98.
Grinspoon, S. and Carr, A. (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults, N. Engl. J. Med., 352, 48–62.
Conway, B. (2006) Delavirdine. In: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (Skowron, G. and Ogde, R., eds.), Humana Press, Totowa, NJ, pp. 375–400.
Yeni, P. G., Hammer, S. M., Hirsch, M. S., et al. (2004) Treatment of adult HIV infection: 2004 recommendation of the International AIDS Society-USA Panel, J. Am. Med. Assoc., 292, 251–265.
Wood, E., Hogg, R. S., Harrigan, P. R., and Montaner, J. S. (2005) When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients, Lancet Infect. Dis., 5, 407–414.
Busti, A. J., Hall, R. G., and Margolis, D. M. (2004) Atazanavir for the treatment of human immunodeficiency virus infection, Pharmacotherapy, 24, 1732–1747.
Eron, J. J., Feinberg, J., Kessler, H. A., et al. (2004) Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naïve HIV-positive patients: a 48-week randomized clinical trial, J. Infect. Dis., 189, 265–272.
Wainberg, M. A. and Clotet, B. (2007) Immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review, AIDS Patient Care and STDs, 21(9), 609–620.
Bucy, R. P., Hockett, R. D., Derdeyn, C. A., et al. (1999) Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues, J. Clin. Microbiol., 103, 1391–1398.
Ensoli, F., Fiorelli, V., Alario, C., et al. (2000) Decreased T cell apoptosis and T cell recovery during highly active antiretroviral therapy (HAART), Clin. Imunol., 97, 9–20.
Estaquier, J., Lelievre, J. D., Petit, F., et al. (2002) Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death, J. Virol., 76, 5966–5973.
Steinberg, H. N., Crumpacker, C. S., and Chatis, P. A. (1991) In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus, J. Virol., 65, 1765–1769.
Isgro, A., Mezzaroma, I., Aiuti, A., et al. (2000) Recovery of hematopoietic activity in bone marrow from human immunodeficiency virus type 1-infected patients during highly active antiretroviral therapy, AIDS Res. Hum. Retroviruses, 16, 1471–1479.
Lederman, M., Connick, E., Landay, A, et al. (1997) Partial immune reconstitution after 12 weeks of HAART (AZT, 3TC, ritonavir): preliminary results of ACTG 315, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22–26 [abstract LB13].
Rosenberg, E. S., Billingsley, J. M., Caliendo, A. M., et al. (1997) Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia, Science, 27, 1447–1450.
Connors, M., Kovacs, J. A., Krevat, S., et al. (1997) HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies, Nat. Med., 3, 533–540.
Jacobson, M. A., Kramer, F., Pavan, P. R., Owens, S., and Pollard, R. (1997) Failure of highly active antiretroviral therapy (HAART) to prevent CMV retinitis despite marked CD4 count increase, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22–26 [abstract 353].
Gilquin, J., Piketty, C., Thomas, V., Gonzales-Canali, G., Kazatchine, M. D. (1997) Acute CMV infection in AIDS patients receiving combination therapy involving protease inhibitors, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22–26 [abstract 354].
Finzi, D., Hermankova, M., Pierson, T., et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy, Science, 278, 1295–1300.
Wong, J. K., Hezareh, M., Gunthard, H. F., et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia, Science, 278, 1291–1295.
Chun, T. W., Stuyver, L., Mizell, S. B., et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy, Proc. Natl. Acad. Sci. U.S.A., 94, 13193–13197.
Cavert, W., Staskus, K., Zupancic, M., et al. (1997) Quantitative in situ hybridization measurement of HIV-1 RNA clearance kinetics from lymphoid tissue cellular compartments during triple-drug therapy, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22–26 [abstract LB9].
Wong, J. K., Gunthard, H. F., Havlir, D. V., et al. (1997) Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure, Proc. Natl. Acad. Sci. U.S.A., 94, 12574–12579.
Chun, T. W., Carruth, L., Finzi, D., et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection, Nature, 387, 183–188.
Perelson, A. S., Essunger, P., Cao, Y., et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy, Nature, 387, 188–191.
Havlir, D. V., Hirsch, M., Collier, A., et al. (1998) Randomized trial of indinavir (IDV) vs. zidovudine (ZDV)/lamivudine (3TC) vs. IDV/ZDV/3TC maintenance therapy after induction IDV/ADV/3TC therapy, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5; 225 [abstract LB16].
Raffi, F., Pialoux, G., Brun-Vezinet, F., et al. (1998) Results of TRILEGE trial, a comparison of three maintenance regimens for HIV infected adults receiving induction therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV), 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5; 225 [abstract LB15].
Grabar, S., Le Moing, V., Goujard, C., et al. (2000) Clinical outcome of patients with HIV-1 infection accorfing to immunologic and virologic response after 6 months of highly active antiretroviral therapy, Ann. Intern. Med., 133, 401–410.
Piketty, C., Castiel, P., Belec, L., et al. (1998) Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease, AIDS, 12, 745–750.
Piketty, C., Weiss, L., Thomas, F., et al. (2001) Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen, J. Infect. Dis., 183, 1328–1335.
Negredo, E., Molto, J., Burger, D., et al. (2004) Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load, AIDS, 18, 459–463.
Negredo, E., Bonjoch, A., Paredes, R., et al. (2005) Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies, Clin. Infect. Dis., 41, 901–905.
Pruvost, A., Negredo, E., Benech, H., et al. (2005) Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients, Antimicrob. Agents Chemother., 49, 1907–1914.
Benveniste, O., Flahault, A., Rollot, F., et al. (2005) Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads, J. Infect. Dis., 191, 1670–1679.
Marziali, M., De Santis, W., Carello, R., et al. (2006) T-cell homeostasis alteration in HIV-1 infected subjects with low CD4+ T-cell count despite undetectable virus load during HAART, AIDS, 20, 2033–2041.
Maggiolo, F., Ravasio, L., Ripamonti, D., et al. (2005) Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors, Clin. Infect. Dis., 40, 158–163.
Bangsberg, D. R. (2006) Less than 90% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression, Clin. Infect. Dis., 43, 939–941.
Robbins, G. K., De Gruttola, V., Shafer, R. W., et al. (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection, N. Engl. J. Med., 349, 2293–2303.
Gulick, R. M. (2006) Adherence to antiretroviral therapy: how much is enough? Clin. Infect. Dis., 43, 942–944.
El-Sadr, W. and Neaton, J., for the SMART Study Group (2006) Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART Study, 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5–8 [abstract 106LB].
Lundgren, J. D., for the SMART Study Group (2006) Progression of HIV-related disease or death (POD) in the randomized SMART Study: why was the risk of POD greater in the CD4-guided [(Re)-initiate ART at CD4<250 cells/μL] drug conservation (DC) vs. the virological suppression (VS) arm? XVIth International Conference on AIDS, Toronto, Canada, August 13–16 [abstract WEAB0203].
Burman, W., for the SMART Study Group (2006) The effect of episodic CD4-guided antiretroviral therapy on quality of life: results of the quality of life substudy of SMART, XVIth International Conference on AIDS, Toronto, Canada, August 13–18 [abstract 18588].
El-Sadr, W. M., Lundgren, J. D., Neaton, J. D., et al. (2006) CD4+ count-guided interruption of antiretroviral treatment, N. Engl. J. Med., 355, 2283–2296.
Gulick, R., Su, Z., Flexner, C., Hughes, M., Skolnik, P., Godfrey, C., Greaves, W., Wilkin, T., Gross, R., Coakley, E., Zolopa, A., Hirsch, M., and Kuritzkes, D., for the ACTG 5211 Study Team (2006) ACTG 5211: Phase II study of the safety and efficacy of vicriviroc in HIV-infected treatment-experienced subjects, XVIth International Conference on AIDS, Toronto, Canada, August 13–18 [abstract THLB0217].
Ridler, S. A., Haubrich, R., DiRienzo, G., Peeples, L., Powderly, W. G., Klingman, K. L., Garren, K. W., George, T., Rooney, J. F., Brizz, B., Havlir, D., and Mellors, J. W., for the AIDS Clinical Trials Group 5142 Study Team (2006) A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection, XVIth International AIDS Conference, Toronto, Canada, August 13–18 [abstract THLB0204].
Torriani, F. J., Parker, R. A., Murphy, R. L., Fichtenbaum, C. J., Currier, J. S., Dubé, M. P., Squires, K. E., Gerschenson, M., Komarow, L., Cotter, B. R., Mitchell, C. K., and Stein, J. H., for the ACTG 5152s Team (2005) A5152s a substudy of A5142: antiretroviral therapy improves endothelial function in individuals with human immunodeficiency virus infection: a prospective, randomized multicenter trial (Adult AIDS Clinical Trials Group Study), American Heart Association Scientific Session, Dallas, TX, November 11–13 [abstract PS5].
MacArthur, R. D., Novak, R. M., Peng, G., Chen, L., Xiang, Y., Kozal, M. J., van den Berg-Wolf, M., Henely, C., Huppler-Hullsiek, K., Schmetter, B., and Dehlinger, M., for the CPCRA 058 Study Team and the Terry Beirn Communit
Swindells, S., DiRienzo, G., Wilkin, T., Fletcher, C. V., Margolis, D. M., Thal, G. D., Godfrey, C., Bastow, B., Ray, M. G., Wang, H., Coombs, R. W., McKinnon, J., and Mellors, J. W., for the AIDS Clinical Trials Group 5201 Study Team (2006) A prospective, open-label, pilot trial of regimen simplification to atazanavir/ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppresion, J. Am. Med. Assoc., 296(7), 806–814.
Ribaudo, H., Kuritzkes, D., Lalama, C., Schouten, J., Schackman, B., Gullick, R., AIDS Clinical Trials Group (2006) Efavirenz (EFV)-based regimens are potent in treatment-naïve subjects across a wide range of pre-treatment HIV-1 RNA (VL) and CD4 cell counts: 3-year results from ACTG 5095, XVIth International Conference on AIDS, Toronto, Canada, August 13–18 [abstract THLB0211].
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Georgiev, V.S. (2009). HIV Therapeutics: Antiretroviral Drugs and Immune-Based Therapies. In: Georgiev, V.S. (eds) National Institute of Allergy and Infectious Diseases, NIH. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-60327-297-1_34
Download citation
DOI: https://doi.org/10.1007/978-1-60327-297-1_34
Publisher Name: Humana Press
Print ISBN: 978-1-60327-296-4
Online ISBN: 978-1-60327-297-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)